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ABSTRACT 
New treatments are required for severe breathlessness in advanced disease. We conducted a 
randomised feasibility trial of mirtazapine over 28 days in adults with a modified Medical Research 
Council breathlessness scale score ≥3. Sixty-four patients were randomised (409 screened), 
achieving our primary feasibility endpoint of recruitment. Most patients had COPD or ILD; 52 (81%) 
completed the trial. There were no differences between placebo and mirtazapine in tolerability or 
safety, and blinding was maintained. Worst breathlessness ratings at day 28 (primary clinical 
activity endpoint) were, 7.1 (s.d. 2.3, placebo) and 6.3 (s.d.1.8, mirtazapine). A phase III trial of 
mirtazapine is indicated.
Trial registration: ISRCTN 32236160; European Clinical Trials Database (EudraCT no: 2015-004064-
11)
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Key points:
 What is the key question?
Is a randomised double-blind, placebo-controlled, dose-escalation trial of mirtazapine feasible 
and acceptable in people with advanced disease who are severely affected by chronic 
breathlessness?
 What is the bottom line?
A randomised double-blind, placebo-controlled phase III trial of mirtazapine is feasible, 
acceptable and desirable in this population. There were relatively high proportions of patients 
screened who were then recruited (16%); data and study completion were aided by dedicated 
research teams offering the option of home visits. 45% of those recruited had dose escalation at 
day 14. Mirtazapine was well tolerated. Results have enabled design of a large international 
phase III trial.
 Why read on?
Currently, morphine is the only drug authorized anywhere in the world (Australia) to reduce 
breathlessness in advanced disease. A wider range of alternatives are needed; repurposing 
medicines offers a cost-effective option, but trials are difficult to conduct. Our data provide 
guidance for future definitive trials, which are now planned. 
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INTRODUCTION
Breathlessness is a prevalent and distressing symptom, associated with considerable disability, 
social isolation, emergency service use and poor survival.1 2 It often persists despite optimum 
pharmacological treatment of the underlying medical condition and non-drug approaches.1 3 4 Drug 
treatments are limited; opioids have the best evidence,5 6 but concerns remain regarding long-term 
effects. New treatments are required. Antidepressants impact on neurotransmitters involved in 
various brain circuits potentially affecting breathlessness, and are worthy of consideration.7 Data 
are mixed for selective serotonin re-uptake inhibitors, with positive case series but a negative 
randomised controlled trial.8 9 Mirtazapine is an antagonist at α2-adrenergic, H1, 5HT2A/C and 
5HT3 receptors, resulting in serotonin, noradrenaline and dopamine release.7 
Thus, we conducted a multi-centre, randomised, placebo-controlled, double-blind, parallel-group, 
dose-escalating, mixed-methods, feasibility trial of mirtazapine for patients severely affected by 
breathlessness, to inform a potential phase III trial.
METHODS
For full details, see the Trial Protocol, online Document S1.
Participants
Patients were recruited from three centres. Inclusion criteria were consenting adults with a 
confirmed diagnosis (by hospitals/clinicians) of chronic obstructive pulmonary disease (COPD), 
interstitial lung disease (ILD), cancer or chronic heart failure, plus clinician assessed modified 
medical research council (mMRC) breathlessness score of 3 or 4 despite optimal treatment of 
underlying disease(s) and prognosis of ≥2 months. Main exclusion criteria were existing 
antidepressant use and  contra-indications to mirtazapine.
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Trial design and procedures
Participants were randomised (1:1) to receive oral mirtazapine (15mg/day (evening)) or placebo 
(capsules identical in appearance, smell and taste) for 28 days. Randomisation was stratified by 
disease (cancer vs. non-cancer), Hospital Anxiety and Depression Score (HADS) score (≥15 vs. <15), 
and taking opioids (yes vs. no).
The primary endpoint was number of patients recruited across three hospitals over 12 months, 
with a target of 60. Secondary endpoints, including proposed primary and secondary clinical activity 
outcomes for a main trial are in online Box S1. Assessments were at baseline and weekly thereafter, 
and included evaluation of breathlessness and related activity scales, toxicity, treatment adherence 
and quality of life. At 14 days, if the rating of worst breathlessness during the previous 24 hours had 
not improved ≥1 point on the 0–10 numerical rating scale (NRS) over baseline, the daily dose was 
increased to two capsules (placebo or 30mg mirtazapine).
Semi-structured qualitative interviews with a purposive sample of participants, aiming to include a 
mix of diseases, experiences and backgrounds (subject to data saturation), see trial protocol, online 
document S1 (page 77) explored experiences of, and motivations for trial participation, the 
intervention and study measures.
The trial received appropriate approvals from the Medicines & Healthcare products Regulatory 
Agency, London Central Research Ethics Committee (16/LO/0091), local research governance and 
registrations; International Standard Randomised Controlled Trial (32236160); EU Clinical Trials 
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Register (2015-004064-11); adopted onto the National Institute for Health Research portfolio 
(30471).
Analysis
For the statistical analysis of the primary endpoint (feasibility), we predetermined 60 patients had to 
be recruited over 12 months across the centres. This sample size took into account the likely number 
required for a fully powered phase III trial, guidance on feasibility designs, and number needed to 
estimate the overall standard deviation for the phase III primary outcome of worst breathlessness.10 
As a feasibility trial, all quantitative endpoints were summarised descriptively, with no formal 
statistical comparisons between groups.
Qualitative data were audio recorded, transcribed verbatim and analysed following the framework 
method (see online Document S1.)
RESULTS
Recruitment and progress through trial
Each centre opened for 12 months; 409 patients were screened for eligibility and 64 randomised 
(16% of those screened; mean 5.3 per month) achieving the primary outcome of feasibility (Figure 
1). Most participants had COPD (64%) or ILD (31%), and mMRC Grade 4 (58%); 33% were taking 
opioids and HADS score was ≥15 in 24 (38%). Demographics and clinical characteristics were 
balanced between randomised groups (online Tables S1, S2). 
(insert figure 1 about here.)
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Main reasons for ineligibility were existing antidepressant use (38%), mMRC score <3 (27%). Eighty-
three (20% of 409 screened) patients declined participation. Reasons were mainly not liking the 
idea of a clinical (18%) or a blinded (7%) trial, not wanting to take additional medicine (18%), 
already having too much to think about (17%) and not liking the thought of antidepressants (13%).
All randomised participants received at least one dose of mirtazapine or placebo, none were lost to 
follow-up (Figure 1). Fifty-two participants (81%) remained on treatment all 28 days. Twenty-nine 
participants (45%) dose escalated at day 14; based on the same criteria at day 28, 21 participants 
(33%) would have been eligible for further dose escalation.
Twelve patients (6 per arm) discontinued treatment prematurely. The Bang Blinding Index (BBI), 
which calculates differences between correct and incorrect guesses for unblinding (see online Box 
S1), was 0.31 [95% CI 0.03, 0.59] and 0.21 (95% CI -0.07, 0.50) in the placebo and mirtazapine arms 
respectively.
Toxicity and safety
There were few adverse events, with only one grade 3 reported (insomnia, day 28, placebo arm). 
There were 12 Serious Adverse Events (SAEs) in 9 participants (mean 1.3 per person, SD 0.71; 
mirtazapine: four people (7 events), placebo: five people (5 events)). Only o e SAE (a fall, with 
grade 2 dizziness and confusion) was assessed as being related to trial medication (placebo arm). 
Two patients died during the study, after 27 (mirtazapine) and 20 (placebo) days from baseline, 
both due to their underlying illness.
Other outcome data
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There were little missing data (online Table S3). At baseline, mean scores for worst breathlessness 
NRS were similar across treatment arms, with standard deviation of 1.52 informing the phase III 
sample size calculation. Worst breathlessness improved in both groups at day 7,  staying similar 
subsequently (Figure 2). Other outcomes also showed small changes over time (Table 1, online 
Figure S1).
Table 1. Clinical activity outcomes and costs at day 28 of study by trial arm
NRS=numerical rating scale/10. CRQ=Chronic Respiratory Disease Questionnaire.  HRQL=Health-
related Quality of Life. EQ-5D=quality of life. IPOS= Integrated Palliative care Outcome Scale. HADS= 
Hospital Anxiety and Depression Scale. GSES= General Self-Efficacy Scale. SPPB= Short Physical 
Performance Battery.
‡Scale interpretation: high score worse. *Scale interpretation: high score better. †CRQ sub-domains 
Mirtazapine 
n = 30
Placebo 
n = 34
Clinical activity outcomes – mean (standard deviation)
NRS worst (last 24 hours)‡ day 28
       change from baseline to day 28 mean (95% confidence 
interval)
6.3 (1.8)
-1.3 (-2.1 - -0.5)
7.1 (2.3)
-0.8 (-1.6 - 0.0)
NRS average (last 24 hours)‡ day 28
       change from baseline to day 28 mean (95% confidence 
interval)
4.7 (2.0)
-0.7 (-1.2 - -0.2)
4.9 (1.8)
0.0 (-0.7 - 0.7)
IPOS total‡ day 28 17.2 (8.0) 17.8 (7.6)
HADS anxiety‡ day 28 4.3 (2.8) 5.3 (3.5)
HADS depression‡ day 28 6.1 (3.3) 6.5 (3.7)
SPPB*$  day 28 7.6 (2.1) 7.4 (2.9)
CRQ dyspnoea*†# day 28
CRQ emotion*† day 28
3.1 (1.1)
5.0 (1.2)
2.8 (1.0)
4.9 (1.3)
CRQ fatigue*† day 28 3.8 (1.3) 4.0 (1.2)
CRQ mastery *† day 28 4.9 (1.2) 4.9 (1.3)
GSES total score* day 28 31.4 (5.1) 30.7 (4.8)
Economic measures – mean (standard deviation)
EQ-5D* day 28
        change from baseline to day 28 mean (95% confidence 
interval)
0.61 (0.26)
0.07 (0.00 - 0.15)
0.63 (0.15)
0.03 (-0.04 - 0.09)
EQ-5D VAS* day 28 63.4 (21.2) 60.8 (19.0)  
Health and social care costs (£) in the previous 1 month‡ 522 (773) 412 (529)
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(Insert figure 2 about here)
Qualitative data
Interviews were conducted with 22 participants (11 COPD, 8 ILD, 3 other) of whom two withdrew 
early because of adverse effects,  see online Box S2 for summary findings.
DISCUSSION
This feasibility trial successfully achieved its primary endpoint based on numbers recruited from 
three sites over one year, a pragmatic outcome based on completing a phase III study in a 
reasonable time. Uptake and data collection were high and attrition low for a population with 
advanced disease.3 5 9 Qualitative data suggest this is partly due to having dedicated research staff. 
The tolerability and safety of mirtazapine were good with little apparent loss of participant blinding 
(BBI close to zero in both arms). Our data have been used to inform development of an 
international multicentre phase III trial; this has secured funding.
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Titles and legends for Figures which are attached separately
Figure 1. Consolidated Standards of Reporting Trials flow diagram of patients included in the trial, 
follow up and analysis.
Footnotes
# = reasons why 7 patients were consented but not randomised were because they were found or 
became ineligible: started pulmonary rehabilitation (1); uncontrolled diabetes mellitus (2), started 
taking antidepressants(1), hepatic impairment(1), decided not on optimal treatment for underlying 
condition(1), and 1 missing. 
* Of those who discontinued intervention, patients were willing to continue data collection in all 
but 1 in the mirtazapine group and all but 4 in the placebo group, all available data were analysed.  
Figure 2. Mean (95% confidence interval) breathlessness at worst and average over 24 hours 
during the 28 weeks of the study, by study arm
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Lost to follow up (n= 0) 
 
Discontinued intervention (n=6) 
 Participant choice (n=6), note that one of these 
discontinued and died shortly afterwards, at day 20  
Analysed* (n=34) 
 
Analysis 
Follow-Up 
Analysed* (n=30) 
 
Lost to follow-up (n= 0) 
 
Discontinued intervention (n=6) 
 Participant choice (n=5) 
 Participant died, at day 27 (n=1) 
 
Assessed for eligibility (n=409) Excluded (n=345) 
   Not approached because not 
eligible at initial screening  
(n=142) 
  Approached but found not to be  
eligible at interview (n=110) 
   Consented but not randomised as 
found/became ineligible (n=7, #) 
   Declined to participate (n=83) 
   Not able to be contacted (n=2) 
   Died suddenly before follow-up 
call (n=1) 
 
Allocated to mirtazapine (n=30) 
 Received mirtazapine (n=30) 
 Did not receive mirtazapine (n=0) 
Allocated to placebo (n= 34) 
 Received placebo (n=34) 
 Did not receive placebo (n=0 ) 
Allocation 
Randomised (n=64) 
Enrollment 
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Online Document S1– BETTER-B Feasibility Protocol
                                    
BETTER-B (Feasibility) Protocol, Version 2.0, 11 February 2016
BETTER-B Feasibility: 
BETter TreatmEnts for Refractory Breathlessness
A feasibility study of the use of mirtazapine for refractory 
breathlessness
EudraCT Number: 2015-004064-11
ISRCTN Number: 32236160
REC Reference: 16/LO/0091
Sponsors: King’s College London and King’s College Hospital NHS Foundation Trust 
Funded by: Marie Curie Cancer Care, Cancer Research UK (Grant Ref: A18859)
Supported by: Yorkshire Cancer Research 
National Institute for Health and Care Excellence (NIHR)
Cicely Saunders International 
Chief Investigator: Prof Irene J. Higginson, Professor of Palliative Care, 
King’s College London, Cicely Saunders Institute, 
Department of Palliative Care, Policy & Rehabilitation, 
Bessemer Road, Denmark Hill, London, SE5 9PJ
The Sponsors and Clinical Trials Research Unit (CTRU) accept no responsibility for the accuracy of content 
reproduced from this protocol and incorporated into additional documentation developed by collaborating or 
third party organisations.
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BETTER-B (Feasibility) Protocol, Version 2.0, 11 February 2016
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London SE1 9RT
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University of Leeds
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University of Leeds
Data Management (for queries regarding eligibility, treatment, CRF and data query completion, SAE 
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University of Leeds
Statistics
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Clinical Advisors
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Trial Summary
Trial Title (Full) BETTER-B (Feasibility): BETter TreatmEnts for Refractory Breathlessness: A 
feasibility study of the use of mirtazapine for refractory breathlessness
Trial Title (Short) BETTER-B (Feasibility): BETter TreatmEnts for Refractory Breathlessness
Trial Acronym BETTER-B (Feasibility)
Trial Backgrou d Breathlessness (also called dyspnea or dyspnoea) is a common, distressing 
symptom in advanced disease, particularly those affecting the heart and 
lungs, causing considerable disability for patients, and anxiety and social 
isolation for them and their family and carers. Breathlessness which 
continues despite optimal management of the underlying causes and current 
symptom relief measures, is termed ‘intractable’ or ‘refractory’. It generally 
worsens as the disease progresses and is one of the most frightening 
aspects facing a person with advanced disease. 
Over 2 million people experience breathlessness each year in the UK. This 
includes more than 90% of the over 1 million people in the UK diagnosed with 
moderate to severe chronic lung disease, over 50% of the 200,000+ with 
incurable cancer and 50% of the 2 million with chronic heart failure (many of 
whom will suffer refractory breathlessness). Breathlessness is associated 
with shortened life expectancy and often results in emergency visits and 
hospitalisation.
There are few effective treatments for refractory breathlessness, thus, 
refractory breathlessness represents a huge unmet need and new 
approaches are desperately required. Morphine has a role, but there are no 
other proven pharmacological treatments. Preliminary data suggest that 
serotonergic modulation is beneficial but rigorous evaluation has not been 
conducted. There is therefore a ne d to explore the potential role of 
antidepressants in this setting.
Mirtazapine is a widely used noradrenergic and specific serotonergic 
antidepressant (NaSSA). There is clinical experience to support its use in 
anxiety and panic disorder and clinical evidence for its use in major 
depressive disorders associated with anxiety.
BETTER-B (Feasibility) will help address this unmet need by exploring if 
mirtazapine has a role in the management of refractory breathlessness in 
patients with cancer, chronic obstructive pulmonary disease, interstitial lung 
disease, or chronic heart failure. If successful, a larger trial will be conducted.
Trial Design A randomised (1:1) placebo-controlled, double-blind, mixed-methods, 
multicentre (3 trial sites) feasibility trial.
Trial Aim The aim of the study is to determine the feasibility of performing a large-scale 
double-blind, placebo-controlled randomised trial of mirtazapine for refractory 
breathlessness.
Trial Endpoints Primary endpoint:
 Number of patients recruited across 3 trial sites over a 12-month 
period
Secondary endpoints:
 Feasibility
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 Activity
 Safety and toxicity
 Symptoms and Quality of Life: 
Ancillary study:
 Qualitative Interviews
Trial Population 60 participants suffering from severe refractory breathlessness, diagnosed 
with cancer, lung disease (COPD/ILD) or chronic heart failure.
Randomisation Randomisation (1:1) to the placebo arm or the active arm (mirtazapine) will 
be carried out by the Clinical Trials Research Unit (CTRU), Leeds at baseline 
prior to starting treatment.
Trial Treatment All participants are planned to receive 28 days of trial treatment, taking 1 
capsule of trial drug (placebo or 15mg mirtazapine) daily.
After an initial 14 days of treatment, participants will be assessed for 
suitability to escalate their dose. If deemed suitable, participants will increase 
their dose to 2 capsules daily (placebo or 30mg mirtazapine).
Duration Trial recruitment will continue for 12 months and be followed by a short 
follow-up period (until the last randomised participant’s follow-up 
assessment).
Evaluation of 
outcome measures
Participants will be assessed (either by phone or in person) every 7 days 
during trial treatment (day 7, 21 and 28) and then have a follow-up 
assessment (by phone) 7 days after their last trial drug dose. 
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Trial Schema
Randomisation & start trial treatment (≤7 days after eligibility)
Baseline assessments (≤7 days prior to randomisation/start treatment): mMRC, AKPS, NRS, 
CRQ, IPOS, EQ-5D-5L, HADS, SPPB, GSES, CSRI and full medical history
Day 7 assessment call (+/- 1working day): CRQ, trial drug compliance, opioid medication, toxicity
Day 14 assessment visit (+/- 1working day): mMRC, AKPS, NRS, CRQ, HADS, trial drug compliance, 
opioid medication, toxicity, suitability for dose-escalation
Day 21 assessment call (+/- 1working day): CRQ, trial drug compliance, opioid medication, toxicity
Day 28 assessment visit (- 1working day): mMRC, AKPS, NRS, CRQ, IPOS, EQ-5D-5L, HADS, SPPB, GSES, 
CSRI, trial drug compliance, opioid medication, toxicity, suitability for dose-escalation, blinding assessment
Follow-up assessment call (7days after la t trial dose; +1 working day): oxicity
If 
>7
 d
ay
s,
 a
ll 
el
ig
ib
ili
ty
 
as
se
ss
m
en
ts
 m
us
t b
e 
re
pe
at
ed
 
pr
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r t
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nd
om
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n 
an
d 
st
ar
tin
g 
tr
ea
tm
en
t
YES
NO
NO
Add patient 
details to trial 
Screening Log
Obtaining Full Informed Consent
Has the patient provided written informed consent after further discussions?
NO YES
Formal Eligibility Assessment
Does the patient meet all of the inclusion criteria and none of the 
exclusion criteria? 
YES
Identification of Potential Participants
By recruiting trial sites, or by PICs; alternatively patients may contact a recruiting trial site directly (trial publicity). Potential 
participants include those who have been diagnosed with cancer, COPD/ILD or chronic heart failure, with a prognosis of 
≥2months and severe breathlessness (i.e. anticipated mMRC score of Grade 3 or 4)
Initial Approach
Is the patient interested in participating in principle?
Preliminary Eligibility Assessment
Is the patient potentially eligible, based on preliminary available information? (e.g. no existing antidepressant use, etc.)
YESNO
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Abbreviations
AE Adverse Event
AKPS Australia-modified Karnofsky Performance Scale
AR Adverse Reaction
ATS American Thoracic Society
CI Chief Investigator
COPD Chronic Obstructive Pulmonary Disease
CRF Case Report Form
CRQ Chronic Respiratory Questionnaire
CSRI Client Services Receipt Inventory
CTA Clinical Trial Authorisation
CTCAE Common Terminology Criteria for Adverse Events
CTD Connective Tissue Disease
CTRU Clinical Trials Research Unit
DMEC Data Monitoring & Ethics Committee
DSUR Dev lopment Safety Update Report
ETS European Respiratory Society
GCP Good Clinical Practice
GSES Generalized Self-Efficacy Scale
GSTFT Guy’s and St Thomas’ NHS Foundation Trust
HADS Hospital Anxiety and Depression Scale
ICF Informed Consent Form
ICMJE International Committee of Medical Journal Editors
ILD Interstitial Lung Disease
IME Important Medical Event
IMP Investigational Medicinal Product
IPF Idiopathic Pulmonary Fibrosis
IPOS Integrated Palliative care Outcome Scale
ITT Intention To Treat
MAO-I Monoamine Oxidase Inhibitor
MDT Multi-Disciplinary Teams
MedDRA Medical Dictionary for Regulatory Activities
MHRA Medicines and Healthcare products Regulatory Authority
mMRC modified Medical Research Council
NaSSA Noradrenergic and Specific Serotonergic Antidepressant
NCI National Cancer Institute
NCRI National Cancer Research Institute
NICE National Institute for Health and Care Excellence
NRS Numerical Rating Scale
NYHA New York Heart Association
PI Principal Investigator
PIC Participants Identification Centre
PIS Participant Information Sheet
PSL Participant Summary Leaflet
QALY Quality Adjusted Life Year
QoL Quality of Life
REC Research Ethics Committee
SAE Serious Adverse Event
SAR Serious Adverse Reaction
SOP Standard Operating Procedure
SPC Summary of Product Characteristics
SPPB Short Physical Performance Battery
SSOP Study Site Operating Procedure
SSRI Selective Serotonin Re-uptake Inhibitor
SUSAR Suspected Unexpected Serious Adverse Reaction
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Background  
1.1 Breathlessness 
Breathlessness is a common, distressing symptom in life-limiting conditions, particularly those 
affecting the heart and lungs, causing considerable disability for patients [1-3], and anxiety and 
social isolation for them and their family and carers [4-6]. Breathlessness (also called dyspnea 
or dyspnoea) is usually described as: “a subjective experience of breathing discomfort that 
consists of qualitatively distinct sensations that vary in intensity. The experience derives from 
interaction among multiple physiological, psychological, social, and environmental factors and 
may induce secondary physiological and behavioural responses” [1]. Breathlessness which 
continues despite optimal management of the underlying causes and current symptom relief 
measures, is termed ‘intractable’ or ‘refractory’. It generally worsens as the disease progresses 
and is one of the most frightening aspects facing a person with advanced disease. Caregivers 
often report a feeling of helplessness while watching their loved ones suffer; clinicians too 
experience similar feelings due to the lack of effective interventions [4-6].
Over 2 million people experience breathlessness each year in the UK. This includes more than 
90% of the over 1 million people in the UK diagnosed with moderate to severe chronic lung 
disease, over 50% of the 200,000+ with incurable cancer and 50% of the 2 million with chronic 
heart failure (many of whom will suffer refractory breathlessness) [7-10]. In addition, 
breathlessness is found in people severely affected by renal and liver failure, neurological 
conditions, HIV/AIDS and many autoimmune diseases [8, 11-13]. Breathlessness increases as 
the disease progresses [14, 15], is associated with shortened life expectancy [16-18], is very 
frightening for patients and families [5, 6, 9, 10, 19] and often results in emergency visits and 
hospitalisation [3, 20-22].
1.2 Treatments
There are few effective treatments for refractory breathlessness. Morphine has a role [23-29], but 
there are no other proven pharmacological treatments. Animal studies, case reports, 
observational series and a phase II trial of 10 patients suggest that serotonergic modulation is 
beneficial [30-34], but rigorous evaluation has not been conducted.
Opioids, oxygen and benzodiazepines
The most relevant reviews are available for opioids, oxygen and benzodiazepines [29, 35-38]. 
Although opioids by mouth and injection can reduce breathlessness, optimal dosing, titration 
and potential issues arising from longer term use (e.g. safety, tolerance, dependence, misuse) 
remain to be determined. Further, not all patients may be suitable for, or want them [27, 29, 39], 
especially those with non-malignant disease. In one Dutch study, only 2% of people with 
advanced Chronic Obstructive Pulmonary Disease (COPD) were prescribed strong opioids [9]. 
Evidence does not support the use of nebulized opioids or transmucosal fentanyl [29, 38]. Benefit 
Page 30 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 15          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
from oxygen is similar to medical air in mildly or non-hypoxaemic breathless patients with 
various diseases, and there are limitations to its use (e.g. safety, cost) [40]. The evidence 
currently does not support a role for benzodiazepines [37]. Thus, the need remains to develop 
new palliative approaches with fewer limitations.
Antidepressants
Antidepressants are an attractive option to explore, particularly given their low risk of 
respiratory depression and dependence [30]. There are no systematic reviews relating to such 
use. Data is limited, but animal work [32] and case series of patients with chronic breathlessness 
reporting improvement in breathlessness ± exercise tolerance with older tricyclic 
antidepressants (TCA) or selective serotonin re-uptake inhibitor (SSRI) antidepressants [30, 31, 
33], suggest that serotonin plays a role in the control of respiration and generation/perception 
of breathlessness. The exact mechanism is unclear; a reduction in sensitivity to CO2 has been 
reported [41]; ultimately it probably involves modulation of brain stem centres responsible for 
respiratory rhythm and/or of centres involved in the perception of breathlessness [31]. 
Benefit does not appear to relate to antidepressant or anxiolytic effects per se, as 
improvements in breathlessness are also reported by patients without concurrent anxiety 
and/or depression [31, 33, 42]. However, manipulation of serotonin in patients with panic disorder 
reduces experimentally induced panic (using CO2 challenges) and given that ‘respiratory 
anxiety and panic’ are common in patients with chronic breathlessness, this could be relevant 
[41].
Mirtazapine
Mirtazapine is a widely used noradrenergic and specific serotonergic antidepressant (NaSSA). 
It antagonises receptors (α2, 5HT2A and 5HT2C) which inhibit the release of serotonin, 
noradrenaline and dopamine [43, 44]. In addition, it antagonizes H1- and 5HT3- receptors.
Mirtazapine is a commonly used antidepressant with good data supporting its efficacy, 
acceptability and safety in the treatment of depressive illness [31, 42, 45]. There is clinical 
experience to support its use in anxiety and panic disorder and clinical evidence for its use in 
major depressive disorders associated with anxiety [46]. 
It is an antidepressant which appears to have a quicker onset of action and fewer drug 
interactions than other antidepressants, has a good safety record and may be better tolerated 
than other antidepressants in this population [45-50]. It also has the added advantage of reducing 
anxiety [47-49, 51], which is a common consequence of severe episodes of breathlessness [52-54]. 
Mirtazapine is increasingly preferred over SSRIs (and other antidepressants) in advanced 
disease because it appears to have a quicker onset of action [45] and it has fewer undesirable 
effects leading to early discontinuation, fewer drug interactions and is not associated with 
cardiovascular toxicity or sexual dysfunction [55]. 
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Further, it also has appetite stimulation, anti-emetic and analgesic properties, which could be 
of particular benefit to patients with advanced disease, and the side effect of weight gain may 
also be an advantage for some patients who have weight loss in advanced disease [50, 51, 56-59]. 
Thus, mirtazapine is a promising alternative to SSRIs to test in this setting.
1.3 Current Research and Rationale for BETTER-B Feasibility 
Trial
Despite an increase in the understanding of the mechanisms associated with the generation 
and perception of breathlessness, this has not yet translated into effective new treatment 
options [1]. Thus, refractory breathlessness represents a huge unmet need and new 
approaches are desperately required. Authoritative guidelines have highlighted the need for 
interdisciplinary research to test new treatments in sufficiently powered clinical trials. They 
have also stressed the importance of not limiting potentially universally beneficial approaches 
to one particular patient group [1, 35, 36, 60-62].
There is a need to explore the potential role of antidepressants in this setting. Existing data is 
limited, but reflects that SSRIs (e.g. sertraline) are now generally preferred over TCAs from a 
tolerability point of view [50, 55-58]. A search of current trial databases on the management of 
breathlessness (and dyspnoea), including clinicaltrials.gov and controlled-trials.com, and 
contact with leaders in the field identified one study of morphine (Johnson), one relevant phase 
II [34] and one phase III study of sertraline [63] (Currow, personal communication) and no studies 
of mirtazapine. Currow’s randomised trial in Australia is testing sertraline in the management 
of breathlessness across several conditions following promising phase II data [34, 63]. This 
trial, recruiting in 12 hospitals, has (as of October 2015) 160 patients randomised (total needed 
220), and 107 completed (total needed 150). However, as a partner in this application, the 
Australian group has raised concerns that because of the many contra-indications for sertraline 
use, the number of potential drug interactions and undesirable effects, many otherwise eligible 
patients are excluded from the trial, leading not only to slow recruitment (first patient enrolled 
January 2011), but more importantly, to concerns that the results may have limited 
generalisability. Thus, BETTER-B will test a different category of antidepressant in this setting, 
one which may have advantages over sertraline and other SSRIs.
Preliminary data suggest that serotonergic modulation is beneficial but rigorous evaluation has 
not been conducted. BETTER-B will help address this need by exploring if mirtazapine has a 
role in the management of refractory breathlessness in patients with cancer, chronic 
obstructive pulmonary disease, interstitial lung disease, or chronic heart failure. 
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1.4 Justification for Double-Blind Feasibility Trial
Breathlessness is a complex, multifactorial experience and is reported as a subjective 
measure, and refractory breathlessness is a feature of advanced disease where participants 
may suffer from adverse events due to their underlying condition(s). Therefore, in order to gain 
a measure of the benefits and harms of an intervention in a trial, a placebo control is needed. 
A large-scale trial was considered, however in light of the uncertainty around recruitment, 
blinding and attrition in this trial, and in order to obtain an estimate of likely activity of this drug 
to inform the design of the large-scale trial, a feasibility trial was deemed necessary first. This 
feasibility trial will determine whether a large-scale trial in this advanced illness setting can be 
performed. The trial is placebo-controlled and double-blind, to reflect exactly the proposed 
design of a subsequent large-scale trial. A 7-day follow-up period has been chosen in order to 
provide sufficient data on recruitment and retention for a large-scale trial. 
The results of this trial will be used to determine the feasibility of proceeding with a large 
randomised, placebo-controlled, double-blind trial of approximately 250 patients in this setting 
and this population and the best methods/design for that study. They will inform future studies 
in patients with advanced diseases, especially recruitment and trial design, and advance our 
understanding of breathlessness and ways to research it.
A formal feasibility  trial design was not deemed necessary as there is evidence of the activity 
and safety of other similar drugs in the same class as mirtazapine, providing preliminary 
evidence that a large-scale trial of mirtazapine is warranted (see section 1.2 and personal 
confidential communication, Currow et al., Trial Management Group member).
Aims and Objectives
This is a randomised placebo-controlled, double-blind, mixed-methods feasibility trial of 
mirtazapine for refractory breathlessness in 60 patients with a diagnosis of cancer, chronic 
obstructive pulmonary disease (COPD), interstitial lung disease (ILD) or chronic heart failure.
1.5 Aims
The aim of the trial is to determine the feasibility of performing a large-scale double-blind, 
placebo-controlled randomised trial of mirtazapine for refractory breathlessness. 
1.6 Primary Objective
The primary objective is to determine whether a randomised, double-blind, placebo-controlled 
large-scale trial of mirtazapine for refractory breathlessness is feasible in terms of recruitment, 
as assessed by the number of patients recruited across 3 hospitals over a 12-month period.
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1.7 Secondary Objectives
1.7.1 Feasibility
To quantitatively assess a number of other aspects of feasibility, which will be used to 
determine whether the current design is suitable to be taken forward to a large-scale trial. To 
be assessed in terms of:
 Recruitment in different settings: outpatient, community services and inpatient settings
 Acceptability of randomisation to patients
 Ability to deliver placebo-control and maintain the double-blind
 Ability to assess outcome measures and minimise missing data for the future large-
scale trial
 Compliance with treatment
1.7.2 Activity, Quality of Life and Toxicity
To obtain average and worst breathlessness severity estimates (measured using Numerical 
Rating Scale (NRS)) on day 28 to inform the sample size calculations for the future large-scale 
trial. 
To determine patient eligibility to increase the dose of mirtazapine further at 28 days.  
To assess the potential activity and impact on the activity of mirtazapine and quality of life 
(QoL) for patients with refractory breathlessness using the following tools:
 Breathlessness mastery: Chronic Respiratory Questionnaire (CRQ) and modified 
Medical Research Council (mMRC) dyspnoea scale [64] on days 14 and 28;
 Lower extremity functioning: Short Physical Performance Battery (SPPB) [65] on day 
28 [66];
 Coping self-belief assessment: Generalized Self-Efficacy Scale (GSES) [67] on day 28;
 Palliative symptoms: Integrated Palliative care Outcome Scale (IPOS) on days 14 and 
28;
 Anxiety and depression: Hospital Anxiety and Depression Scale (HADS) on days 14 
and 28;
 QoL: EQ-5D-5L on day 28 and Australia-modified Karnofsky Performance Scale 
(AKPS) [68] on days 14 and 28; 
 Health Economics: Client Services Receipt Inventory (CSRI) on day 28; 
 Opioid medication: on days 7, 14, 21 and 28; 
To monitor adverse reactions, using the Common Terminology Criteria for Adverse Events 
(CTCAE) categorisation (v4) [69], on days 7, 14, 21 and 28, in order to evaluate the toxicity 
profile of mirtazapine in patients with refractory breathlessness.
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If we are able to demonstrate feasibility within this trial, i.e. the ability to recruit an average of 
5 patients per month within a 12-month period (approximately 60 patients) then we plan to 
seek funding to run a larger double-blind, placebo-controlled randomised trial. Secondary 
outcome measures of feasibility will be assessed to determine whether the design of the future 
large-scale trial may need to be adapted to improve recruitment or reduce attrition. Physical 
activity and toxicity outcomes will be used to inform the design of the future trial however they 
will not be used to inform the decision as to whether or not to proceed to a larger scale trial. 
The primary aim of the future trial would be to determine whether mirtazapine improves 
breathlessness in patients with refractory breathlessness compared to placebo, based on 
breathlessness severity at day 28 as the primary outcome measure. 
1.7.3 Qualitative Interview Sub-study
We will conduct interviews with a sub-set of patients to explore acceptability of trial procedures, 
materials and intervention for patients and clinicians, and the main impact, if any, of the 
intervention to enhance recruitment procedures, and ensure that the outcome measures are 
appropriate for a large-scale trial. 
Design
The trial is designed as a multi-centre, randomised, placebo-controlled, double-blind, mixed-
methods feasibility trial. It is planned to recruit approximately 60 participants with refractory 
breathlessness over a 12-month period from approximately three UK trial sites. 
Participants will be randomised via minimisation on a 1:1 ratio to receive either oral mirtazapine 
(15mg/day) or placebo medication for 28 days. 
At day 14 of treatment breathlessness intensity (“at worst” over the previous 24 hours) will be 
assessed using the numerical rating scale (NRS). This will be assessed by a member of the 
research team. If there is no improvement in NRS (i.e. NRS does not increase by 1 point or 
more compared to baseline NRS) and the drug has been well tolerated, the daily dose of 
treatment will be doubled. 
Participants will be followed up for 7 days after completing trial treatment to assess safety and 
toxicity of treatment. 
All participants, trial site research teams and pharmacies will be blinded to participants’ 
treatment allocation to minimise possible bias. Further information regarding blinding can be 
found in section 0.
Eligibility
Eligibility waivers to inclusion and exclusion criteria are not permitted.
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1.8 Inclusion Criteria
Male or female aged ≥ 18 years old
 Diagnosed with:
 Cancer, or
 Chronic obstructive pulmonary disease (COPD), or
 Interstitial lung disease (ILD), or
 Chronic heart failure (New York Heart Association (NYHA) class III or IV)
Breathlessness severity: Modified MRC dyspnoea scale grade 3 or 4 (i.e. stops for 
breath after walking about 100 yards or after a few minutes on level ground, or is too 
breathless to leave the house or is breathless when dressing) .
On optimal treatment of the underlying condition in the opinion of the identifying clinician 
(see section 1.12.3 of protocol for guidance) 
Management of the underlying condition unchanged for the previous 1 week
Reversible causes of breathlessness optimally treated in the opinion of the identifying 
cliniciani
Expected prognosis of ≥2 months
If female, must be (as documented in patient notes):
a)      postmenopausal (no menses for 12 months without an alternative medical 
cause), or
b)      surgically sterile (hysterectomy, bilateral salpingectomy or bilateral 
oophorectomy), or
c)      using acceptable contraception ii (which must be continued for 7 days after 
the last dose of IMP)
Able to complete questionnaires and trial assessments
Able to provide written informed consent
1.9 Exclusion Criteria
1. Existing antidepressant useiii, use of linezolid, or St John’s wort
i According to the current appropriate society national guidance.
ii Acceptable contraception is defined as one of the following: combined (estrogen and progestogen containing) 
hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal); progestogen-
only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine 
device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; 
practising true abstinence (when this is in line with the preferred and usual lifestyle of the subject).
iii Previous antidepressant use is permitted provided there is a wash-out period of 14 days prior to randomisation.
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2. Known contraindication to mirtazapineiv
3. Hypersensitivity to the active substance or to any of the components of the 
mirtazapine or placebo (e.g. lactose intolerance)
4. Australia modified Karnofsky Performance Scale ≤40v
5. Pregnant or breast-feeding women vi
6. Patients with acute cardiac events within 3 months of randomisation (myocardial 
infarction, unstable angina pectoris, or significant cardiac conduction disturbance)
7. Patients with known hepatic impairment
8. Patients with known renal impairment
9. Patients with uncontrolled blood pressure
10. Patients with uncontrolled diabetes mellitus
11. Patients with uncontrolled seizures, epilepsy or organic brain syndrome
12. Patients with severe depression or suicidal thoughts
13. Patients with a history of psychotic illness (schizophrenia, bipolar disorder, mania or 
hypomania, or other psychotic disturbances)
Recruitment Process
1.10 Recruitment Setting
Participants will be recruited from approximately three trial sites with trial coordination and data 
collection performed by the Clinical Trials Research Unit (CTRU) in Leeds. Participants may 
be identified from within the trial sites, or referred to the trial sites by community services, 
hospices and various other settings (e.g. patient support groups, etc.) Trial sites will be 
required to have obtained management approval and undertake a site initiation meeting with 
the Sponsor, and CTRU prior to the start of recruitment into the trial. Screening and recruitment 
iv One class of contraindicated concomitant medications listed in the mirtazapine Summary of Product 
Characteristics (SPC) are monoamine oxidase inhibitors (MAO-Is). Where a patient has previously taken a MAO-
I, they must not be treated with mirtazapine for 14 days from the last dose.
v i.e. in bed more than 50% of the time, due to association with short survival.
vi for women of childbearing potential (those not post-menopausal or surgically sterile) must be confirmed by a 
pregnancy test within 7 days prior to randomisation
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processes must not be initiated at site until approval to open to recruitment has been formally 
issued by the CTRU.
The trial aims to recruit 60 participants over a 12-month period.
1.11 Screening
Patients diagnosed with cancer, heart failure or lung disease (COPD or ILD) and who have 
significant breathlessnessvii will be screened for trial entry. All participating trial sites will be 
required to complete monthly Screening Logs of all patients screened for entry into the trial 
who do not go on to be randomised. This information will be collected from trial sites on a 
regular basis. Documented reasons for ineligibility or declining participation will be closely 
monitored by the CTRU. 
1.12 Informed Consent and Eligibility
The Principal Investigator (PI) will retain overall responsibility for the informed consent of 
participants at their site and must ensure that any person delegated responsibility to participate 
in the informed consent process is duly authorised, trained and competent to participate 
according to the ethically approved protocol, principles of Good Clinical Practice and 
Declaration of Helsinki 1996. Informed consent must be obtained by the PI, or another 
medically qualified member of the team authorised to consent by the PI on the BETTER-B 
delegation log, prior to the participant undergoing procedures that are specifically for the 
purposes of the trial and are not standard routine care at the participating site.
Assenting participants will be broadly assessed for eligibility during the screening process 
based on their medical history according to the inclusion and exclusion criteria.
The right of a patient to refuse participation without giving reasons will be respected. The 
participant must remain free to withdraw at any time from the trial without giving reasons and 
without prejudicing his/her further treatment, and will be provided with a contact point where 
he/she may obtain further information about the trial. Where a participant is required to re-
consent, or new information is required to be provided to a participant, it is the responsibility 
of the PI to ensure this is done in a timely manner and according to any timelines requested 
by the CTRU.
As this is a feasibility trial, we will investigate reasons why patients decline to participate using 
a Feedback questionnaire: completion of this questionnaire is entirely optional. Patients who 
vii For the purposes of this protocol, “significant breathlessness” is defined as an anticipated score of grade 3 or 
grade 4 on the modified Medical Research Council (mMRC) dyspnoea scale.
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decline entry into the trial are provided with the questionnaire and an envelope in which they 
can seal their completed questionnaire before returning to the research team. The 
questionnaire is provided at the time the patient refuses participation; this may be when they 
are first approached or after they have had time to consider the participant information sheet. 
There is also a planned qualitative sub-study which will involve patients being interviewed (see 
Appendix D). Patients who decline to participate in the trial will still be eligible for this sub-
study. For those decliners who choose to complete the Feedback questionnaire, there is a 
section therein for them to indicate if they would be happy to be approached for this sub-study 
at a future time. For those who do decide to participate in the main trial, the trial consent form 
includes a section for them to indicate if they would be happy to be approached for this sub-
study.
1.12.1 Initial Information and Initial Approach
Potential participants may be identified through a variety of methods: by staff at the recruiting 
site itself (e.g. through hospital clinic lists, searching of existing hospital databases, cancer 
Multi-Disciplinary Teams (MDT) meetings, etc.), by staff at Participants Identification Centres 
(PICs), and through the use of trial publicity in various settings (e.g. hospices, patient support 
groups, etc.). 
The use of existing hospital databases of patients who have previously consented to be 
contacted about research may be used and initial contact with these patients will be in-line 
with what they had previously agreed with that site (e.g. initial contact by phone, or by letter, 
etc.). Potential participants identified through such databases may be contacted directly by the 
trial site’s research team (if such contact has previously been agreed by the patient), or 
alternatively may be approached via an ‘Invitation’ Letter which will provide contact details of 
the recruiting site’s research team. Brief trial information in the form of a Participant Summary 
Leaflet (PSL) will also be provided. 
Potential participants identified at a PIC, who agree to receive further information about the 
trial, will be provided with the PSL and will be asked if their details may be passed on to the 
research team at the nearest recruiting site so they can be contacted. If the potential participant 
is interested in participating in the trial, they will also be provided with the contact details of the 
research team so they can themselves contact the recruiting site’s research team directly if 
they so choose. 
Trial publicity (posters and PSLs) will also be available in various NHS and non-NHS settings 
(non-NHS hospices, patient support groups, etc.) and these will include contact details of the 
nearest recruiting site’s research team. Potential participants may directly contact a recruiting 
site’s research team via the use of such publicity. 
Once the potential participant has been contacted by, or have themselves contacted, the 
recruiting site’s research team, an appointment will be made to meet with a member of the 
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research team to discuss the trial further. At this visit, they will be provided with further verbal 
explanation of the trial, the Participant Information Sheet (PIS) and Informed Consent Form 
(ICF), which include detailed information about the rationale, design and personal 
implications of the trial.
1.12.2 Consent Process
Following initial information provision, participants will have as long as they need to consider 
participation in the trial (usually at least 24 hours) and will be given the opportunity to discuss 
the trial with their family and other healthcare professionals before they are asked whether 
they would be willing to take part in the trial.
Assenting potential participants will be invited to provide written informed consent. The PI or 
any other delegated medic who has received Good Clinical Practice (GCP) training and is 
authorised on the trial Delegation Log is permitted to take informed consent for trial 
participation. 
Where the patient is able to provide fully informed consent but is unable to sign or otherwise 
mark the consent form, provision for completion of the consent form by a witness will be made. 
This should be a carer, friend/family member, or a local member of the clinical team who is 
independent of the research team.
A record of the consent process detailing the date of consent and all those present will be kept 
in the participant’s medical notes. The original signed consent form(s) will be filed in the 
Investigator Site File, a copy will be given to the participant, a copy will be returned to the 
CTRU and another copy will be filed in the hospital notes (as per local practice).
Where valid informed consent is obtained from the participant and the participant subsequently 
becomes unable to provide ongoing informed consent by virtue of physical or mental 
incapacity, the consent previously given when capable remains legally valid. Participants who 
lose capacity after informed consent has been obtained will continue with protocol treatment, 
assessments and follow-up in consultation with the PI and participant’s carer / family with the 
participant’s best interests foremost in the decision-making process. Ongoing collection of 
safety and follow-up data will continue via the clinical care team for inclusion in the trial analysis 
in order to preserve the integrity of the trial’s intention to treat analysis and fulfil regulatory 
requirements specifically for pharmacovigilance purposes. The PI will take responsibility for 
ensuring that all vulnerable subjects are protected and participate voluntarily in an environment 
free from coercion or undue influence.
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1.12.3 Eligibility Process
The following assessments must be carried out prior to randomisation in order to establish 
eligibility (see section 0  above for full eligibility criteria): 
 Medical review (including medical history, assessment of management of the 
underlying disease and concomitant medication use)
 mMRC dyspnoea scale assessment
 AKPS assessment
 Pregnancy test for women of childbearing potential (those not post-menopausal 
or surgically sterile)
The assessment of whether the participant is receiving optimal treatment for their underlying 
disease is to be made by the identifying clinician and should be based on the following 
guidance:
 For COPD or ILD:viii
o On optimal immunosuppression for Connective Tissue Disease 
(CTD) ILD
o On pirfenidone for IPF if suitable [70, 71].
o On oxygen if hypoxic at rest or on activity
o On appropriate treatment for pulmonary hypertension, if applicable
o Had pulmonary rehabilitation if appropriate.
 For heart failure:
o Reached target dose (or be on maximally tolerated dose, or be 
intolerant) of an inhibitor of the renin-angiotensin system shown to 
improve prognosis;
AND
o Reached target dose (or be on maximally tolerated dose, or be 
intolerant) of a beta adrenoceptor antagonist shown to improve 
prognosis;
AND
o Reached target dose (or be on maximally tolerated dose, or be 
intolerant) of an aldosterone antagonist.
 For cancer: chemotherapy, radiotherapy or other anti-cancer treatment not 
currently appropriate or planned, as assessed at MDT meeting including 
oncologists, surgeons and relevant specialists, with review of radiological and 
histological data.
viii Based on NICE Idiopathic Pulmonary Fibrosis (IPF) / pirfenidone guidelines, British Thoracic Society ILD 
guidelines (includes CTD assoc ILD), American Thoracic Society (ATS) / European Respiratory Society (ERS) 
guideline ILD.
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Informed consent must be obtained prior to undertaking any trial-specific procedures, 
including non-routine eligibility assessments. All eligibility assessments must be performed 
no more than 7 days prior to the participant being randomised and beginning trial treatment. 
Where more than 7 days have elapsed since the initial eligibility assessments, these must be 
repeated prior to randomisation and the participant beginning trial treatment; if these 
repeated assessments show ineligibility, the patient must not be randomised into the trial.
1.13 Randomisation
1.13.1 Timing of Randomisation
Informed written consent for entry into the trial must be obtained, and baseline assessmentsix 
performed prior to randomisation. Following confirmation of written informed consent and 
eligibility, participants will be randomised into the trial by an authorised member of staff at the 
trial site. Randomisation will be performed centrally using the CTRU 9:00 – 17:0-00 (office 
hours)x randomisation system and should take place as soon as possible after consent is 
obtained and eligibility confirmed, and no more than 7 days prior to the start date of trial 
treatment.xi 
1.13.2 Treatment Allocation
Participants will be randomised on a 1:1 basis to receive either mirtazapine or placebo and will 
be allocated a trial number and a unique kit-code to identify which container of trial drug 
(mirtazapine or placebo) will be dispensed. The participant’s randomisation allocation will not 
be disclosed in order to maintain the blinding of the trial.
A computer-generated minimisation programme that incorporates a random element will be 
used to ensure that treatment groups are well balanced by:
 Disease (cancer vs non-cancer)
 HADS score (≥15 vs <15)
 Currently receiving opioids (yes vs no)
ix It is important that baseline assessments are performed prior to randomisation, as the HADS score is used as a 
minimisation factor.
x Exceptions: public / bank holidays, the period between Christmas Eve and New Year, Thursday afternoon before 
Good Friday and all Tuesdays following a bank holiday except for Mayday and New Year’s Day.
xi Where this is not possible, the eligibility assessments must be repeated so that they are no more than 7 days old 
at the time of starting treatment; if the repeated assessments show ineligibility, the patient must not be entered into 
the trial.
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1.13.3 Randomisation Process
Randomisation should take place as soon as possible after consent is obtained and eligibility 
confirmed, and must be performed by an authorised member of the team at the site using the 
CTRU office hours telephone randomisation service (open 9:00 to 17:00 Monday to Friday, 
excluding public / bank holidays, the period between Christmas Eve and New Year, Thursday 
afternoon before Good Friday and all Tuesdays following a bank holiday except for Mayday 
and New Year’s Day). 
The following information is required in order for the participant to be randomised. The person 
making the randomisation telephone call should have all details to hand:
 Name and code (assigned by the CTRU) of trial site 
 Patient initials and date of birth
 Confirmation of eligibility 
 Confirmation of written informed consent
 Minimisation factors (see section 1.13.2 above)
Direct line for office hours randomisation
0113 343 1486
Please ensure that you have completed the Initial Eligibility Checklist and 
Randomisation Case Report Forms (CRFs) before telephoning
At the end of this phone call a unique BETTER-B trial participant identifier will be assigned but 
the participant’s randomisation allocation will not be disclosed in order to maintain the blinding 
of the trial. Instead, a unique kit-code will be provided which identifies a container of capsules 
that need to be dispensed by pharmacy. 
1.13.4 Post-Randomisation Actions
At the end of the randomising phone call, the trial participant identifier and kit-code number 
must be added to the Randomisation Case Report Form (CRF) and all participant details must 
be added to the main Participant ID Log. 
Two Confirmation of Randomisation notifications, detailing the participant details and the kit-
code number they have been allocated will be sent to site: one to the nominated contact in the 
local research team and another to pharmacy. These should be filed in the Investigator Site 
File and Pharmacy Site File, respectively. The kit-code provided will inform pharmacy which 
container of capsules needs to be dispensed to the participant. These notifications are 
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generated and sent from the CTRU. In the event of a system failure, the kit-code number may 
need to be provided to the pharmacy directly by the member of site staff randomising the 
participant (this information will be provided as part of the randomising phone-call). 
Trial Medicinal Product Management
Please refer to the BETTER-B Pharmacy and Investigational Medicinal Product (IMP) Study 
Site Operating Procedure (SSOP) for full details of the trial IMP management requirements. 
Within the trial the following are classed as IMPs:
Mirtazapine
 Composition: one capsule contains 15mg of mirtazapine. 
 Supplied by Medreich Plc.
Placebo 
 Composition: gelatin capsule shell containing lactose.
 Manufactured by Guy’s and St Thomas’ NHS Foundation Trust’s (GSTFT) Pharmacy 
Production Unit.
For handling guidance of both mirtazapine and placebo, please refer to the latest Summary of 
Product Characteristics (SPC) for mirtazapine (as supplied by Medreich Plc; PL number 
21880/0053).
1.14 GSTFT Manufacture, packaging and Labelling
The Pharmacy Production Unit at GSTFT will act as the trial’s Central Pharmacy and holds a 
Manufacturer’s Authorisation for IMPs.
The trial IMP placebo will be manufactured by the trial Central Pharmacy. The trial IMP 
mirtazapine will be sourced by the Central Pharmacy where the capsules will be over-
encapsulated in such a way that they are identical to the placebo capsules in order to maintain 
the blind of the trial. 
The Central Pharmacy will also package up the trial IMPs (each container will hold 42 capsules 
or either placebo or over-encapsulated mirtazapine) and label the containers. In order to 
maintain the blinding of the trial the capsules and containers will be identical and labelled with 
the same study-specific label in accordance with Directive 2001/20/EC and the Medicines for 
Human Use (Clinical Trials) Regulations 2004 (as amended).  
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Containers will be identified only by a unique kit-code assigned at random. Management of kit-
codes on the kit logistics application will be conducted by the CTRU Trial Statistician in addition 
to maintaining the back-up kit-code lists for each site. The CTRU Trial Statistician will be 
responsible for maintaining this list, which will be securely password-protected when treatment 
information is contained within the list. 
1.15 Supply, Distribution and Storage
Trial IMPs (mirtazapine and placebo) will be provided to sites free of charge for use in this 
clinical trial. Blinded supplies will be sent to trial sites from Central Pharmacy (see above) in 
pre-labelled containers which will be identifiable by a kit-code printed on the label. In addition 
to the trial IMP containers, sites will receive sealed Code-Break Envelopes to allow emergency 
unblindings where necessary. Each envelope will be linked to a specific container of trial IMP 
capsules using the unique kit-code system. See section 1.19 below for further details on 
emergency unblinding.
Once received from the trial Central Pharmacy, all trial IMP stock and Code-Break Envelopes 
must be documented as received in accordance with the BETTER-B Pharmacy and IMP SSOP 
provided within the BETTER-B Pharmacy Site File. 
All trial IMP containers must be stored in a secure ring-fenced location within the site 
pharmacy. There are no special storage requirements in terms of temperature management.
The supply of trial IMPs (mirtazapine and placebo) must not be used for any purpose 
other than that outlined in this protocol and should be clearly ring-fenced from standard 
hospital stock.
1.16 Dispensing
In order to maintain the blinding of the trial the site pharmacist ill not be told the participant’s 
treatment allocation. Blinded containers of capsules, identifiable only by a unique kit-code are 
received at site pharmacies from the Central Pharmacy and will be stored in a ring-fenced 
section of the site pharmacy until dispensing. To ensure that the correct treatment is dispensed 
to the participant the relevant site pharmacist will be told which container to dispense to each 
participant using this kit-code numbering system. 
The relevant site pharmacist will be notified by the CTRU of all participants randomised at that 
site; each Confirmation of Randomisation notification will detail the participant trial ID number, 
date of birth and initials and also the kit-code assigned to that participant which will identify 
which container of capsules should be given to the participant. The member of the local 
research team randomising the participant will also have been told which kit-code should be 
dispensed to the participant whilst making the randomisation telephone call, and will also 
receive a Confirmation of Randomisation Fax detailing the kit-code. 
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The participant’s trial identifier must be added to the label of each trial IMP container by the 
pharmacist (or authorised delegate) at the time of dispensing, and the Code-Break Envelope 
assigned to that kit-code annotated with the participant details and then securely stored in 
pharmacy.
Dispensing must only be performed by an authorised member of site staff as delegated on the 
trial Pharmacy Authorised Personnel Log. Once randomised, at baseline the participant will 
receive one trial IMP container, containing 42 capsules, of either mirtazapine or placebo, 
identifiable only by the unique kit-code on the outer container label. All dispensed trial IMP 
must be recorded on the trial Accountability and Dispensing Log in accordance with the 
BETTER-B Pharmacy and IMP SSOP.
Each container of trial IMP capsules, identifiable only by the unique kit-code, will have 
a corresponding Code-Break Envelope. Each time a container of capsules is dispensed, 
the participant identifiers must be added to the trial IMP container label and also to the 
corresponding Code-Break Envelope. This Code-Break Envelope will then be held 
securely within the site pharmacy (see section 1.19 for access required in the event of 
unblinding).
1.17 Reconciliation
All trial IMP stock received by site pharmacies from Central Pharmacy, dispensed to trial 
participants (and any returned unused doses from participants) must be recorded on the 
BETTER-B Accountability and Dispensing Logs. These completed logs will be reviewed by 
Sponsor at monitoring visits. Trial IMP stock (dispensed and returned, or un-dispensed) may 
only be destroyed by trial site pharmacies once full reconciliation has been performed by 
Sponsor and formal permission for destruction issued.
Code-Break Envelopes for all trial IMP containers (whether or not dispensed) will be returned 
to CTRU at the end of trial for destruction.
BETTER-B Treatment
1.18 Treatment Details
The local Investigator, the site pharmacist, other members of the site staff involved with the 
trial, and the participants themselves, will remain blinded to the treatment allocation (except 
where emergency unblinding is necessitated).
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1.18.1 Treatment Regimen
Participants will be randomised to receive either mirtazapine or placebo for 28 days. 
Participants will be dispensed 42 capsules (15mg per tablet for mirtazapine) at baseline. 
Participants should take their capsules in the evening. 
For participants randomised to receive mirtazapine, the daily dose will be 15mg (one capsule) 
for the first 14 days; participants will be assessed for possible dose escalation at the trial 
assessment visit for day 14 and if appropriate, their daily dose will be escalated to 30mg (two 
capsules) on days 15 through to 28; see section 0 below for further details.xii Where dose 
escalation is not appropriate, the participant will continue to take a daily dose of 15mg (one 
capsule) on days 15 through to 28. 
For participants randomised to receive placebo the daily dose will be 1 capsule for the first 14 
days; participants will be assessed for possible dose escalation on day 14 and if appropriate, 
their daily dose will be escalated to 2 capsules on days 15 through to 28; see section 0 below 
for further details.xiii Where dose escalation is not appropriate, the participant will continue to 
take a daily dose of 1 capsule on days 15 through to 28.
1.18.2 Treatment Compliance
In order to assess participant compliance with the trial treatment, at the assessment phone-
calls (day 7 and day 21) and visits (day 14 and day 28) the research team will ask the 
participant if they have had any delayed, missed or modified doses. This information will be 
recorded on the appropriate Assessment CRF. Any unused capsules should be collected from 
the participants by the research team at the last assessment visit (day 28)xiv and returned to 
pharmacy for drug reconciliation then destruction (see section 1.17 above for further details).
Participants will be given a medication diary to complete in order to aid in the monitoring of 
treatment compliance. This diary will be given to participants at baseline and they will be asked 
to complete this every day and to bring it along to all trial visits (days 14 and 28) and have it 
available during trial calls (days 7, 21 and follow-up call at 7 days after ending trial treatment).
xii Where dose escalation is deemed appropriate for a participant, and the Day 14 trial visit occurs before the 14th 
day of treatment, the participant must be instructed to begin taking two capsules per day only from day 15 onwards. 
Where dose escalation is deemed appropriate for a participant, and the Day 14 trial visit occurs after the 14th day 
of treatment, the participant must be instructed to begin taking two capsules per day from that point forward until 
the end of their trial treatment (i.e. day 28).
xiii See footnote xii above.
xiv If the Day 28 visit occurs before the 28th day of trial treatment, all capsules should be left with the participant at 
that visit, and another visit arranged for collection of unused capsules after the participant has completed 28 days 
of treatment.
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1.18.3 Concomitant Medications / Interactions
For management of concomitant therapies, please refer to the latest mirtazapine Summary of 
Product Characteristics (produced by Medreich Plc; PL 21880/0053).
Use of MAO inhibitors, linezolid, other antidepressant medication, and St John’s wort are 
prohibited for the participant for the duration of the trial. Furthermore, MAO inhibitors must not 
be used until there has been a 14 day washout period from the last dose of IMP. 
Caution is advised (particularly in relation to dose escalation) when used with inhibitors or 
inducers of CYP3A4, benzodiazepines, alcohol and warfarin.
1.18.4 Most frequent anticipated toxicities
The most frequent anticipated toxicities of mirtazapine are as follows:
 Increased appetite
 Weight gain
 Somnolence
 Sedation
 Headache
 Dry mouth
 Lethargy
 Dizziness
 Tremor
 Nausea
 Diarrhoea
 Vomiting
 Exanthema
 Arthralgia
 Myalgia
 Back pain
 Orthostatic hypotension
 Oedema peripheral
 Fatigue
 Abnormal dreams
 Confusion
 Anxiety
 Insomnia
1.19 Emergency Unblinding
Whilst the safety of participants in the trial must always take priority, maintenance of blinding 
is crucial to the integrity of the trial. Investigators should only break the blind when information 
about the participant‘s trial treatment is clearly necessary for the appropriate medical 
management of the participant and where stopping the blinded medication is not sufficient. 
Unblinding may be requested on the grounds of safety by the Chief Investigator (CI), local PI 
or treating physician. It is anticipated that requests for unblinding will most likely originate from 
a participant, carer (or friend / family member) or personal physician (e.g. GP) at the time of 
an adverse event or planned change in non-trial related drug therapy. Requests for unblinding 
will first be handled by the local PI or delegate who will explore the reason for the request and 
evaluate the importance of knowledge of treatment assignment for participant safety. In the 
Page 48 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 33          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
event of a Serious Adverse Event (SAE), all participants should be treated as though they are 
receiving the active medication.
Should an alternative to unblinding not be identified, and if unblinding is required to optimise 
medical management of the participant, investigators should follow the emergency unblinding 
process. 
Emergency unblinding is provided by the CTRU during Office Hours and the 
participating site pharmacy at all other times, thereby covering each 24-hour period. It 
is encouraged that requests for Emergency Unblinding should be made directly with 
CTRU wherever possible.
The following information will be needed to perform an emergency unblinding:  
 Participant details, including trial ID number, initials and date of birth 
 Name of trial research site and site code 
 Name of person making the request for a code-break 
 Reason for requesting a code-break 
 Confirmation of whether the PI authorised the request 
1.19.1 Emergency Unblinding during Office Hours
The emergency unblinding process will be undertaken by telephoning the CTRU during Office 
Hours, 9.00 to 17.00 Monday to Friday. Exceptions:  public / bank holidays, the period between 
Christmas Eve and New Year, Thursday afternoon before Good Friday and all Tuesdays 
following a bank holiday except for Mayday and New Year’s Day.
  
Following the emergency unblinding of a participant, CTRU will send a notification to the 
requester, the local PI and the Sponsor. The details of the emergency unblinding should be 
recorded on the BETTER-B Unblinding Log provided by CTRU. 
1.19.2 Emergency Unblinding outside of Office Hours
Outside of Office Hours, or where the Investigator or treating physician is unable to contact 
CTRU, emergency unblinding must be performed by the local pharmacy department. The 
responsible pharmacist on duty will complete the Unblind Request CRF, retrieve the code-
Direct line for CTRU emergency unblinding: 0113 343 1486
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break information (Code-Break Envelopes for unblindings will be provided to pharmacy at the 
time of IMP delivery and each envelope will be linked to a specific container of capsules using 
a unique kit-code) and reveal the treatment allocation to the person requesting the unblind. 
The pharmacist must send the completed Unblind Request CRF to the CTRU within 24 hours 
of the unblinding request (please see section 0 for details of acceptable methods of transfer). 
All Code-Break Envelopes will be returned to CTRU by the site pharmacy department at the 
end of trial. Code-Break Envelopes must not be opened for participants when they have 
completed trial therapy.
1.19.3 Treatment of Participants following Emergency Unblinding
Following an emergency unblinding the participant should be treated according to the 
treating clinician’s assessment. 
1.20 Withdrawal of Treatment
In line with usual clinical care, cessation or alteration of regimens at any time will be at the 
discretion of attending clinicians or the participants themselves. All participants withdrawn from 
treatment or prescribed alternative treatment will still attend for follow-up assessments unless 
unwilling to do so and CRFs will continue to be completed.
The PI, or delegate should make every effort to ensure that the specific wishes of any 
participant who wishes to withdraw consent for further involvement in the trial are defined and 
documented using the Withdrawal CRF in order that the correct processes are followed by the 
CTRU and site following the withdrawal of consent. 
It should be made clear to any participant specifically withdrawing consent for further 
data collection that data pertaining to safety will continue to be collected for regulatory 
reporting purposes and will be included in any safety analysis. In addition it is 
suggested that the participant is made aware of the fact that if any significant new 
information becomes available in regard to the treatment they have received in the trial 
it may be necessary to contact them in the future.
Assessments and Data Collection
1.1 Schedule of Events 
The timings of interventions and assessments required for the BETTER-B Feasibility trial are 
summarised in Table 1.
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Table 1: Schedule of Events
Abbreviations: mMRC (modified Medical Research Council), AKPS (Australia-modified Karnofsky Performance Status), Tx (treatment), NRS (Numerical Rating Scale), CRQ 
(Chronic Respiratory Questionnaire), SPPB (Short Physical Performance Battery), GSES (Generalized Self-Efficiency Scale), IPOS (Integrated Palliative care Outcome Scale), 
CSRI (Client Services Receipt Inventory).
TIMEPOINT
Eligibility 
(≤ 7 calendar days 
prior to starting 
treatment)
Baseline
(≤ 7 calendar days 
prior to starting 
treatment)
Day 7 
(+/- 1 working day)
Day 14
(+/- 1 working day)
Day 21
(+/- 1 working day)
Day 28
(-1 working day)
7 days post 
treatment 
end
(+1 working day)
ASSESSMENTS Face-to-face Face-to-face Phone-call Face-to-face Phone-call Face-to-face Phone-call
Demographic data and full medical review [disease, 
prognosis, optimal Tx, concomitant medications, 
contraindications, cardiac history, symptoms] 
X1 X2
Pregnancy test (for women of childbearing potential) X1 X
Randomisation and dispensing X
mMRC dyspnoea scale (participant-reported) X1 X2 X X
CRQ (participant-reported) X X X
GSES (participant-reported) X X
IPOS (participant-reported) X X X
HADS (participant-reported) X X X
CSRI (participant-reported) X X
EQ-5D-5L (participant-reported) X X
NRS (participant-reported) X X X X X
AKPS X1 X2 X X
SPPB X X
Vital signs (blood pressure and blood oxygen level) X X
Toxicity assessment X X X X X X
Opioid medication assessment X X X X X
Mirtazapine compliance assessment (and modifications) X X X X3 X3
Suitability for dose escalation X X
Blinding assessment X
Collection of unused medication X3
1. Eligibility assessments must be no more than 7 days before starting treatment. Where more than 7 days elapse from the initial eligibility assessments, they must be repeated 
before randomisation and starting treatment.
2. Eligibility assessments may be used for baseline so long as they are no more than 7 days old at the time starting treatment.
3. If the participant has not completed 28 days of trial treatment at the time of the Day 28 trial visit, trial IMP compliance will be assessed at the follow-up call (7days after 
completing trial treatment) and an unused trial IMP collected in.
4. If the participant has not completed 28 days of trial treatment at the time of the Day 28 trial visit, another visit must be arranged in order to collect any unused trial IMP.
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1.2 Screening Data 
All patients who have significant breathlessnessxv but do not go on to be randomised must be 
included on the monthly Screening Logxvi. Anonymised information for these patients will be 
collected including: 
 Disease area diagnosis (e.g. cancer, heart or liver disease)
 Identification setting (community services, outpatient clinic, inpatient clinic)
 Method of initial approach
 Date screened 
 Approached / Not approached for the trial
 Reason for non-randomisation: 
o not eligible for trial participation, or
o eligible but declined and reason for this (where appropriate), or 
o other reason for non-randomisation
This information will be collected from trial sites on a monthly basis. Documented reasons for 
ineligibility or declining participation will be closely monitored by the CTRU. Screening data 
forms a crucial endpoint of this feasibility study therefore it is essential that this information is 
completed and returned to CTRU as outlined.
1.3 Eligibility Assessments  
The following assessments need to be performed in order to assess eligibility (see section 0 
above for full eligibility criteria):
 Medical review (including medical history, assessment of management of the 
underlying disease and concomitant medication use)
 Modified Medical Research Council (mMRC) dyspnoea scale assessment
 Australia-modified Karnofsky Performance Scale (AKPS) ≤40
 Pregnancy test for women of childbearing potential (those not post-menopausal or 
surgically sterile)
xv For the purposes of this protocol, “significant breathlessness” is defined as an anticipated score of grade 3 or 
grade 4 on the modified Medical Research Council (mMRC) dyspnoea scale.
xvi If a participant’s screening process spans more than one month, their details should only be included on the 
Screening Log for the month that the screening outcome is final. 
Page 52 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 37          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
Page 53 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 38          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
Eligibility assessments must be no more than 7 days old at the time of starting treatment; if 
more than 7 calendar days elapse from the date of the eligibility assessments and the 
participant has not commenced trial treatment, all eligibility assessments must be repeated. 
For patients who do not go on to be randomised, details should be added to the Screening 
Log (see section 1.11). 
1.4 Baseline Assessments and Data Collection 
Following written informed consent and prior to randomisationxvii, the participant will be 
assessed by a member of the research team and the following baseline assessments will be 
carried out. This visit may be conducted either at the trial site, or, if the participant prefers, at 
the participant’s home / agreed convenient location (e.g. care home, etc.)xviii.
Assessments to be performed by the research team:
 Medical review 
 Australia-modified Karnofsky Performance Scale (AKPS)xix
 Short Physical Performance Battery (SPPB)
 Numerical Rating Scale (NRS) – on average and “at worst” in the last 24 hours 
A number of participant-reported questionnaires will also be completed. These may be 
completed by the participants themselves, or, if preferred, by a member of the research team 
on behalf of the participant. Where this is the case, separate booklets are provided for staff to 
complete, along with a number of laminated “prompt sheets” to be given to the participant to 
facilitate this process: 
 Modified Medical Research Council (mMRC) dyspnoea scalexx
 Chronic Respiratory Questionnaire (CRQ) 
 Integrated Palliative care Outcome Scale (IPOS)
xvii The baseline HADS score will be used at randomisation as a minimisation factor. Ideally, randomisation and 
day 1 of trial treatment should occur on the same day.
xviii Where research team members visit a participant’s home, they should follow their local “lone worker” 
policy to minimise any risks to their personal safety.
xix The AKPS assessment performed for eligibility may be used (this must not be more than 7 days prior to starting 
treatment).
xx The mMRC dyspnoea scale assessment performed for eligibility may be used (this must not be more than 7 
days prior to starting treatment).
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 Hospital Anxiety and Depression Scale (HADS)
 EQ-5D-5L 
 Generalized Self-Efficacy Scale (GSES)
 Client Services Receipt Inventory (CSRI) [72]
1.5 Trial Treatment Assessments and Data Collection  
1.5.1 Day 7 Assessment Phone Call
On day 7xxi of trial treatment, the research team will contact the participant by phone to perform 
the following assessments:
 Numerical Rating Scale (NRS) – on average and “at worst” over the last 24 hours 
 Toxicity assessment: collection of any adverse events or reactions which may have 
occurred since the baseline assessmentxxii
 Opioid medication assessment: collection of information of any opioids taken by the 
participant since the baseline assessment
 Treatment compliance (and any modifications) assessment since the baseline 
assessment (mirtazapine or placebo)
1.5.2 Day 14 Assessment Visit and potential dose escalation
On day 14xxiii of trial treatment, the participant will be seen in person by a member of the 
research team and the following assessments will be carried out. This visit may be conducted 
either at the recruiting trial site, or, if the participant prefers, at another location of their choice 
(e.g. the participant’s home, care home, etc.)xxiv.
Assessments to be performed by the research team:
 Australia-modified Karnofsky Performance Scale (AKPS)
 Numerical Rating Scale (NRS) – on average and “at worst” over the last 24 hours 
xxi Where this phone-call cannot take place on day 7 of treatment, it should be no more than 1 working day either 
side.
xxii Where this toxicity assessment raises any safety concerns, the assessing research team member may 
request that the participant is assessed by a medically qualified member of the team.
xxiii Where this visit cannot take place on day 14 of treatment, it should be no more than 1 working day either side.
xxiv Where research team members visit a participant’s home, they should follow their local “lone worker” 
policy to minimise any risks to their personal safety.
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 Toxicity assessment: collection of any adverse events or reactions which may have 
occurred since the Day 7 assessment callxxv
 Opioid medication assessment: collection of information of any opioids taken by the 
participant since the Day 7 assessment call
 Treatment compliance assessment (and any modifications) since the Day 7 
assessment call (mirtazapine or placebo)
 Assessment of appropriateness to dose escalate (see section 0 below)
 Medical review including vital signs (blood pressure and blood oxygen level)
A number of participant-reported questionnaires will also be completed. These may be 
completed by the participants themselves, or, if preferred, by a member of the research team 
on behalf of the participant. Where this is the case, separate booklets are provided for staff to 
complete, along with a number of laminated “prompt sheets” to be given to the participant to 
facilitate this process. 
 Modified Medical Research Council (mMRC) dyspnoea scale
 Chronic Respiratory Questionnaire (CRQ)
 Integrated Palliative care Outcome Scale (IPOS) 
 Hospital Anxiety and Depression Scale (HADS)
Dose Escalation
All BETTER-B participants will be assessed for dose escalation (to two capsules of mirtazapine 
(30mg total dose) or placebo daily) at their day 14 assessment visit. The assessment of 
suitability for dose escalation will be based on the participant’s NRS score (“at worst” over last 
24 hours), and clinical review. Participants will be eligible for dose escalation where their NRS 
score has not improved by at least 1 point since baseline. If participants have experienced 
toxicity since baseline, they will have a clinical review prior to being assessed as eligible for 
dose escalation.
For participants for whom it is determined that dose escalation is appropriate at the day 14 
assessment visit, they should be instructed by the research team member to begin taking an 
additional capsule every day from day 15 onwardsxxvi (so 2 capsules daily to be taken from day 
15 through to day 28).
xxv Where this toxicity assessment raises any safety concerns, the assessing research team member may 
request that the participant is assessed by a medically qualified member of the team.
xxvi Or from the day of the trial assessment visit, where this occurs after day 14 of trial treatment.
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For participants for whom it is determined dose escalation is not appropriate at the day 14 
assessment visit, they should be instructed to continue to take one capsule daily. 
1.5.3 Day 21 Assessment Phone Call
On day 21xxvii of trial treatment, the research team will contact the participant by phone to 
perform the following assessments:
 Numerical Rating Scale (NRS) – on average and “at worst” over the last 24 hours
 Toxicity assessment: collection of any adverse events or reactions which may have 
occurred since the Day 14 assessment visitxxviii
 Opioid medication assessment since the Day 14 assessment visit
 Treatment compliance assessment (and any modifications) since the Day 14 
assessment visit (mirtazapine or placebo)
1.5.4 Day 28 Assessment Visit
On day 28xxix of trial treatment, the participant will be seen in person by a member of the 
research team and the following assessments will be carried out. This visit may be conducted 
either at the recruiting trial site, or, if the participant prefers, at another location of their choice 
(e.g. the participant’s home, care home, etc.)xxx. 
Assessments to be performed by the research team:
 Australia-modified Karnofsky Performance Scale (AKPS)
 Numerical Rating Scale (NRS) – on average and “at worst” over the last 24 hours
 Short Physical Performance Battery (SPPB)
 Toxicity assessment: collection of any adverse events or reactions which may have 
occurred since the Day 21 assessment callxxxi
xxvii Where this phone-call cannot take place on day 21 of treatment, it should be no more than 1 working day either 
side.
xxviii Where this toxicity assessment raises any safety concerns, the assessing research team member may 
request that the participant is assessed by a medically qualified member of the team.
xxix Where this visit cannot take place on day 28 of treatment, it must not be earlier than day 28 of treatment, and 
should not be more than 1 working day later.
xxx Where research team members visit a participant’s home, they should follow their local “lone worker” 
policy to minimise any risks to their personal safety.
xxxi Where this toxicity assessment raises any safety concerns, the assessing research team member may 
request that the participant is assessed by a medically qualified member of the team.
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 Opioid medication assessment: collection of information (drug name and dose) of any 
opioids taken by the participant since the Day 21 assessment call
 Treatment compliance assessment (and any modifications) since the Day 21 
assessment call (mirtazapine or placebo)
 Assessment of potential to dose escalate 
 Medical review including vital signs (blood pressure and blood oxygen level)
 Pregnancy test for women of childbearing potential (those not post-menopausal or 
surgically sterile)
A number of participant-reported questionnaires will also be completed. These may be 
completed by the participants themselves, or, if preferred, by a member of the research team 
on behalf of the participant. Where this is the case, separate booklets are provided for staff to 
complete, along with a number of laminated “prompt sheets” to be given to the participant to 
facilitate this process. 
 Modified Medical Research Council (mMRC) dyspnoea scale
 Chronic Respiratory Questionnaire (CRQ)
 Integrated Palliative care Outcome Scale (IPOS)
 Hospital Anxiety and Depression Scale (HADS)
 EQ-5D-5L 
 Generalized Self-Efficacy Scale (GSES)
 Client Services Receipt Inventory (CSRI) 
 Blinding Assessment
1.6 Follow-up Assessment and Data Collection 
Participants will be followed-up 7 daysxxxii after the end of trial treatment. The research team 
will contact the participant by phone to perform the following assessments:
 Toxicity assessment: collection of any adverse events or reactions which may have 
occurred since the participant stopped trial treatment
xxxii Where this phone-call cannot take place exactly 7 days after the end of trial treatment, it must not be earlier 
than 7days after completing treatment, and should be no more than 1 working day later.
Page 58 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 43          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
1.7 End of Trial Treatment 
Participants should continue on trial treatment for 28 days, however if a participant 
discontinues trial treatment for any reason before that time, an End of Trial Treatment CRF 
must be completed and sent to the CTRU within 7 days of the research team becoming aware 
of this (please see section 0for details of acceptable methods of transfer). 
1.8 Adverse Events and Serious Adverse Events 
All Adverse Events (AEs) or Adverse Reactions (ARs) occurring in the trial will be collected on 
the weekly Trial Treatment Assessment CRFs and on the Follow-up Assessment CRF. These 
should be reported via the standard data management routes to the CTRU and not expedited.
For all Serious Adverse Events (SAEs) occurring in the trial, a SAE Report CRF must be 
completed and sent to the CTRU within 24 hours of the site becoming aware of the event 
(see pharmacovigilance section 0 and section 0 for details of acceptable methods of transfer).
For all Serious Adverse Reactions (SARs), a SAR Report CRF must be completed and sent 
to the CTRU within 24 hours of the site becoming aware of the event (see pharmacovigilance 
section 0 and section 0 for details of acceptable methods of transfer).
1.9 Pregnancies 
All pregnancies and suspected pregnancies (in a trial participant or their partner) occurring 
from the date of randomisation to 7 days following permanent cessation of trial treatment must 
be reported to the CTRU by completing the Notification of Pregnancy CRF which must be sent 
to the CTRU within 7 days of the site becoming aware of the pregnancy (please see section 
0 for details of acceptable methods of transfer). 
The CTRU will report all pregnancies occurring during trial treatment to the Sponsor along with 
any follow-up information.
1.10 Deaths 
All deaths occurring from the date of randomisation to 7 days after the participant has 
completed trial treatment must be recorded on the Notification of Death CRF and sent to the 
CTRU within 7 days of the site becoming aware of the death (please see section 0 for details 
of acceptable methods of transfer).
At the end of the trial, sites will be contacted to provide data on any subsequent deaths and 
survival data.
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1.11 Important Medical Events (IMEs) 
Events that may not be immediately life-threatening or result in death or hospitalisation, but 
which may jeopardise the patient or require intervention to prevent one of the outcomes listed 
in the definition of a Serious Adverse Event (see section 1.16 below), should also be 
considered serious and should be expedited to the CTRU within 24 hours of the site 
becoming aware.
1.12 Protocol Deviations and Violations 
The CTRU undertake to adopt all reasonable measures to record data in accordance with the 
protocol. Under practical working conditions, however, some minor variations may occur due 
to circumstances beyond the control of the CTRU. All such deviations or violations will be 
documented in the study records, together with the reason for their occurrence; where 
appropriate, deviations or violations will be detailed in the published report. We will analyse 
the reasons for deviations or violations and report on whether and how these might be avoided 
in a future large-scale trial.
1.13 End of Trial Definition 
The end of trial is defined as the date of the collection of the last participant’s last data item, 
i.e. the last participant’s Follow-Up trial phone-call assessment, which will be no earlier than 7 
days after the last participant has completed trial treatment.
1.14 Trial Data and Documentation held at sites 
Participating sites must maintain essential trial documentation in an Investigator Site File and 
a Pharmacy Site File, which will be provided by the CTRU. It is the responsibility of the site 
staff to ensure these files are properly maintained during the trial and archived according to 
Sponsor requirements at the end of the trial (see section 0 on archiving). 
1.15 Case Report Forms (CRFs) 
Data will be recorded by site research staff on trial-specific paper CRFs which will be provided 
by CTRU in the form of an electronic booklet. The originals will be submitted by post to the 
BETTER-B trial team at CTRU within two weeks of the data being collected, and photocopies 
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of the completed CRFs will be held at site. A number of CRFs require expedited reporting to 
the CTRU:
 Within 24 hours of the site research team becoming aware: SAE and SAR CRFs, and 
notification of any IMEs 
 Within 7 days of the research team becoming aware: Death, Notification of Pregnancy 
and End of Trial CRFs 
Only the participant’s trial number, date of birth and initials will be added to the CRFs – site 
staff are responsible for ensuring the CRFs returned to CTRU do not contain any other 
personal identifiable data (with the exception of the participant’s NHS number which will be 
recorded at baseline). Following receipt of the completed CRFs, the CTRU will contact sites 
on a regular basis to resolve any missing or discrepant data.
It is the responsibility of the site to ensure all photocopies of the completed CRFs are 
appropriately maintained at site during the trial (including any amendments) and archived 
according to Sponsor requirements at the end of the trial (see section 0 on archiving).
Pharmacovigilance
1.16 General Definitions
The Medicines for Human Use (Clinical Trials) Regulations 2004 and Amended Regulations 
2006 gives the following definitions:
Adverse Event (AE): any untoward medical occurrence in a subject to whom a medicinal 
product has been administered including occurrences which are not necessarily caused by or 
related to that product. 
An AE can therefore be any unfavourable and unintended sign (Including an abnormal 
laboratory finding, for example), symptom or disease temporarily associated with the use of a 
medicinal product, whether or not considered to be related to the medicinal product.
Adverse Reaction (AR): any untoward and unintended response in a subject to an IMP which 
is related to any dose administered to that subject.
This definition implies a reasonable possibility of a causal relationship between the event and 
the IMP which is supported by facts, evidence or arguments to suggest a causal relationship. 
This definition includes medication errors and uses outside what is foreseen in the protocol 
(i.e. if an AR occurs as a result of a medication error), including misuse and abuse of the 
product.
Page 61 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 46          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
Serious Adverse Event (SAE): any adverse event that:
o Results in death;
o Is life-threatening;
o Required hospitalisation or prolongation of existing hospitalisation;
o Results in persistent or significant disability or incapacity;
o Consists of a congenital anomaly or birth defect.
These characteristics/consequences have to be considered at the time of the event. For 
example, regarding a life-threatening event, this refers to an event in which the subject was at 
risk of death at the time of event; it does not refer to an event which hypothetically might have 
caused death if it were more severe. Medical and scientific judgement must be exercised in 
deciding whether an event is ’serious’ in accordance with these criteria.
Serious Adverse Reactio  (SAR): reference is made to the criterion of ‘Seriousness’ above 
in relation to SAE. Where an SAE is deemed to have been related to an IMP used within the 
trial, the event is termed as a SAR. (Any suspected transmission via a medicinal product of an 
infectious agent is also considered a serious adverse reaction.)
Suspected Unexpected Serious Adverse Reaction (SUSAR): an adverse reaction, the 
nature and severity of which is not consistent with the pharmacovigilance reference copy of 
the mirtazapine SPC (Medreich Plc; PL number 21880/0053).
The term ‘severity’ is used here to describe the intensity of a specific event. This has to be 
distinguished from the term ‘serious’. Reports which add significant information on the 
specificity, increase of occurrence, or severity of a known, already documented serious 
adverse reaction constitute unexpected events.
Important Medical Events (IME) & Pregnancy
Events that may not be immediately life-threatening or result in death or hospitalisation but 
may jeopardise the participant or may require intervention to prevent one of the other 
outcomes listed in the definitions above should also be considered serious.
Although not a serious adverse event, any unplanned pregnancy will also be reported to the 
CTRU in an expedited manner (i.e. within 7 days of the site becoming aware).
Death as a result of disease progression are not considered to be SAEs and should be 
reported in the normal way, on the appropriate CRF.
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1.17 BETTER-B Operational Definitions
Adverse events will be collected for all participants and will be evaluated for intensity 
and causal relationship with the trial medication or other factors according to the National 
Cancer Institute (NCI) CTCAE V4.0 (NCI-CTCAE). A copy is provided in the BETTER-B 
Investigator Site File and may also be obtained at: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
Published date: May 28, 2009
1.17.1 Adverse Events (AEs) / Adverse Reactions (ARs) and Serious 
Adverse Events (SAEs) / Serious Adverse Reactions (SARs)
For general definitions of AEs, ARs, SAEs and SARs, please see section 1.16 above. 
As this is a blinded trial, all AEs and SAEs should be assessed for causal relationship 
assuming that the participant has been receiving mirtazapine.
Routinely breaking the blind could compromise the integrity of the trial. For this reason blind-
breaking will only take place where information about the participant’s trial treatment is clearly 
necessary for the appropriate medical management of the participant. In all cases the 
Investigator would be expected to evaluate the causality of AEs or SAEs as though the 
participant was receiving the active medication. 
When determining whether a SAE or SAR is expected or not, please refer to the 
pharmacovigilance reference copy of the mirtazapine Summary of Product Characteristics 
(SPC) (Medreich Plc; PL number 21880/0053). 
Events not to be classed as SAEs on this BETTER-B Feasibility trial
The following events will not be classed as SAEs within this trial and will therefore not be 
subject to expedited reporting (they will still need to be reported to CTRU along with other 
AEs): 
Hospitalisation or admission into a hospice, nursing home or palliative care unit due to:
 Care-giver burden;
 Expected deterioration related to underlying cancer diagnosis;
 Expected deterioration related to underlying lung disease diagnosis (COPD / ILD);
 Expected deterioration related to underlying chronic heart failure diagnosis (e.g. 
acute decompensation of heart failure, angina with or without raised troponins, 
cardiac arrhythmia Routine treatment or monitoring of the studied indication not 
associated with any deterioration in condition;
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 Treatment which was elective or pre-planned, for a pre-existing condition not 
associated with any deterioration in condition, e.g. pre-planned hip replacement 
operation which does not lead to further complications;
 Any admission to hospital or other institution for general care where there was no 
deterioration in condition;
 Treatment on an emergency, outpatient basis for an event not fulfilling any of the 
definitions of serious as given above and not resulting in hospital admission.
Events classed as expected SAEs / SARs
Examples of events which will be classed as expected SAEs / SARs within this trial are given 
below. These will not be reportable as SUSARs on the trial, unless the severity of the event is 
considered to be unexpected.
This is not intended to be an exhaustive list, therefore when determining whether a SAE / 
SAR is expected or not, the pharmacovigilance reference copy of the mirtazapine SPC 
(Medreich Plc; PL number 21880/0053)  must always be referred to. 
Examples of expected SARs (related to mirtazapine):
 Increase in appetite
 Weight gain
 Somnolence
 Sedation
 Headache
 Dry mouth
All events should be reviewed and classified by the site PI, or another clinically qualified 
member of the medical team authorised in the BETTER-B Delegation Log.
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1.17.2 Suspected Unexpected Serious Adverse Reactions (SUSARs)
For general a definition of SUSARs, please see section 1.16 above. 
SUSARs and will be subject to expedited reporting to the Medicines and Healthcare products 
Regulatory Authority (MHRA) and Research Ethics Committee (REC). 
Events associated with placebo will usually not satisfy the criteria for a SUSAR and therefore 
expedited reporting. However, where SARs are thought to be associated with placebo (e.g. 
reaction due to excipient or impurity) the CTRU will report such cases to the CI for assessment 
of expectedness and, if appropriate, to the Sponsor for onward reporting to the MHRA and 
REC.
Routinely breaking the blind could compromise the integrity of the trial. For this reason blind-
breaking will only take place where information about the participant’s trial treatment is clearly 
necessary for the appropriate medical management of the participant. In all cases the 
Investigator would be expected to evaluate the causality and expectedness of SAEs/SARs as 
though the participant was receiving the active medication. 
1.18 BETTER-B Reporting Requirements
Information about all events (AEs, ARs, SAEs, SARs and SUSARs), whether volunteered by 
the participant, discovered by investigator questioning or detected through physical 
examination, laboratory test or other investigation, must be collected and reported to the 
CTRU. 
All SAEs, SARs and SUSARs (excepting those specified in this protocol as not requiring 
expedited reporting) must be reported immediately (and certainly no later than 24 hours) by 
the trial site team to the CTRU.
For each SAE/SAR or SUSAR the following information will be collected:
 event duration (start and end dates, if applicable)
 action taken
 outcome
 “key information”:
o full details in medical terms and case description (or signs / symptoms / 
diagnosis – i.e. adequate information describing the event)
o seriousness criteria
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o causality (i.e. relatedness to mirtazapine / investigation), in the opinion of 
the investigator
o whether the event would be considered expected or unexpected
o PI signature (or another clinically qualified member of the medical team 
authorised in the BETTER-B Authorised Personnel Log)
All events must be reviewed and assessed (for seriousness, causality and expectedness) by 
the PI, or another clinically qualified member of the medical team authorised in the BETTER-
B Delegation Log. If an authorised medic is not available on the day the site team become 
aware of the event, initial reports without causality and expectedness must still be sent to the 
CTRU within 24 hours of the site becoming aware, and must be followed-up by medical 
assessment as soon as possible thereafter. Any outstanding “key information” (see above) 
must be reported within a further 24 hours. Subsequently, follow-up reports (detailing changes 
in condition) must be reported to the CTRU within 24 hours of the site becoming aware of a 
change relating to “key information”, or at the time of the event resolving or, for all other data, 
when requested by the CTRU.
1.18.1 Reporting of Adverse Events (AEs) and Adverse Reactions (ARs)
All AEs occurring from randomisation up to 7 days after the last dose of trial treatment 
and all ARs occurring from the first trial treatment dose up to 7 days after the last dose 
of trial treatment must be recorded on the appropriate Trial Treatment Assessment CRF or 
Follow-up Assessment CRF, which will be posted to CTRU within 2 weeks of the assessment. 
These are not subject to expedited reporting to CTRU.
1.18.2 Expedited Reporting of Serious Advers  Events (SAEs), Serious 
Adverse Reactions (SARs) and Suspected Unexpected Serious 
Adverse Reactions (SUSARs)
All SAEs, SARs and SUSARs (see section 1.17 above for definitions) must be recorded on 
the appropriate CRF (SAE or SAR) and reported to the CTRU within 24 hours of the local 
research team site staff becoming aware of the event (this includes participants who have 
withdrawn consent for data collection, see section 1.20). Once all resulting queries have been 
resolved, the original wet-ink CRF will be posted to the CTRU and a copy retained at site. 
Please ensure that only one event is reported on each SAE and SAR CRF (details of multiple 
symptoms should be listed if they relate to the same event). 
SAEs, SARs and SUSARs must be reported in an expedited manner (within 24 hours of the 
research team becoming aware) during the active monitoring period, which is defined as 
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occurring from randomisation (for SAEs) or from the first trial treatment dose (for SARs 
and SUSARs) up to 7 days after the last dose of trial treatment. 
If sites become aware of any SARs or SUSARs occurring after this active monitoring period, 
these must still be reported in an expedited manner up until 90 days after the End of Trial. 
1.19 Responsibilities
Principal Investigator:
1. Checking for AEs and ARs when participants attend for treatment / follow-up 
(this may be delegated to an appropriate member of the trial team) and 
ensuring that AEs and ARs are recorded and reported to the CTRU in line with 
the requirements of the protocol.
2. Checking for SAEs when participants attend for treatment / follow-up (this may 
be delegated to an appropriate member of the trial team). 
3. Using medical judgement in assigning seriousness, causality and 
expectedness using the version of the pharmacovigilance reference copy of 
the mirtazapine SPC (Medreich Plc; PL number 21880/0053).
4. Ensuring that all SAEs (occurring up to 7 days after a participant’s last trial 
treatment dose) and SARs, including SUSARs (occurring up to 90 days after 
the End of Trial) are recorded and reported to the CTRU within 24 hours of 
becoming aware of the event and provide further follow-up information as soon 
as available. Ensuring that SAEs and SARs (including SUSARs) are chased 
with CTRU if a record of receipt is not received within 2 working days of initial 
reporting. 
5. Ensuring that SAEs are reported to local committees in line with local 
arrangements.
Chief Investigator (or nominated individual):
1. Clinical oversight of the safety of patients participating in the trial, including an 
ongoing review of the risk / benefit.
2. Using medical judgement in assigning seriousness, causality and 
expectedness of SAEs where it has not been possible to obtain local medical 
assessment.
3. Review of specific SAEs and SARs in accordance with the trial risk assessment 
and protocol as detailed in the Trial Monitoring Plan.
4. Review of all events assessed as SUSARs in the opinion of the local 
investigator. In the event of disagreement between local assessment and the 
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Chief Investigator (CI), local assessment will not be downgraded but the CI 
may add comments prior to reporting to MHRA and REC.
5. Assigning Medical Dictionary for Regulatory Activities (MedDRA) or Body 
System Coding to all SAEs and SARs.
6. The Chief Investigator, with input from CTRU and Sponsor, will submit a 
Development Safety Update Report (DSUR) relating to this trial IMP, to the 
MHRA and REC annually.
CTRU: 
1. Central data collection and verification of AEs and ARs, SAEs, SARs and 
SUSARs according to the trial protocol onto a MACRO database. 
2. Reporting safety information to the independent oversight committee identified 
for the trial (Trial Steering Committee (TSC)) according to the Trial Monitoring 
Plan.
3. Expedited reporting of SUSARs to the MHRA, REC and Sponsor within 
required timelines.
4. Notifying Investigators of SUSARs that occur within the trial.
5. Checking for (annually) and notifying Principal Investigators of updates to the 
Reference Safety Information for the trial.
6. Preparing standard tables and other relevant information for the DSUR in 
collaboration with the CI. 
7. Ensuring timely submission of the DSUR to Sponsor and the REC.
Sponsor:
1. Reporting safety information to the CI, delegate or independent clinical 
reviewer for the ongoing assessment of the risk / benefit according to the 
Sponsor’s Risk Assessment.
2. Ensuring timely submission of the DSUR to the MHRA.
Trial Steering Committee (TSC): 
1. In accordance with the Trial Terms of Reference for the TSC, periodically 
reviewing unblinded overall safety data to determine patterns and trends of 
events or identify safety issues which would not be apparent on an individual 
case basis.
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2. Unblinded safety data would only be discussed in a closed session without 
blinded members of the trial team present.
Participant-reported measures 
The various participant-reported measures (all of which will be administered by the researcher) 
of symptoms, activity, Quality of Life (QoL) and outcomes used in the BETTER-B Feasibility 
trial have been selected based on a national consensus statement of a National Cancer 
Research Institute (NCRI) Group on breathlessness [2], two systematic reviews of measures 
of breathlessness [73, 74], and a study estimating the size of a clinically important difference [25].
Most of these measures are brief scales, with a total of 70 participant-reported questions (at 
baseline), which overall (time for the questions and observation) take around 30-45 minutes 
to complete. This has been found acceptable in other studies [75, 76]. As part of this BETTER-B 
Feasibility trial we will assess which scales are suitable for a future large-scale trial based on 
missing data, patient acceptability and time to complete, so that the questions can be kept to 
a minimum in the future trial. 
The participant-reported measures used in the BETTER-B Feasibility trial are:
 Numerical Rating Scale (NRS) for breathlessness: this assesses the severity of 
breathlessness in the previous 24 hours on a 0-10 numerical rating scale, for average, 
and worst [76]. It will be administered to participants at baseline and at the assessment 
calls/visits for days 7, 14, 21 and 28.
 Modified Medical Research Council (mMRC) dyspnoea scale:[64] this assesses the 
overall level of breathlessness and will be administered to participants at assessment 
visits for days 14 and 28.
 Chronic Respiratory Disease Questionnaire (CRQ):xxxiii this is a 20 item widely 
validated health-related quality of life questionnaire. Experiences are rated on 7-point 
scale ranging  1 (maximum impairment) to 7 (no impairment) [77, 78] This will be 
administered to participants at baseline and at the assessment visits for days 14 and 
28 [74]. 
 EQ-5D-5L: this assesses mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression according to three levels of severity (1=no problems; 2=some or 
moderate problems; 3=extreme problems), plus a Visual Analogue Scale (VAS) of 
current health-related quality of life, scored 0-100.[76] This will be administered to 
participants at baseline and at the assessment visit for days 28.
xxxiii Copyright University Hospitals of Leicester NHS Trust.
Page 69 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 54          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
 Integrated Palliative care Outcome Scale (IPOS):xxxiv this is a brief measure for 
advanced disease widely validated in cancer and non-cancer. Each item is rated 0 (no 
problem) to 4 (overwhelming problem). This will be administered to participants at 
baseline and at the assessment visits for days 14 and 28 [79, 80].
 Generalized Self-Efficacy Scale (GSES):[67] this assesses optimistic self-beliefs to 
cope with a variety of difficult demands in life. This will be administered to participants 
at baseline and at the assessment visit for days 28.
 Hospital Anxiety and Depression Scale (HADS):xxxv this is a widely used and validated 
scale used to assess anxiety and depression and has validity in older people to assess 
change, which will be administered to participants at baseline and at the assessment 
visits for days 14 and 28 [81].
 Client Services Receipt Inventory (CSRI):[72] is an assessment tool where patients 
reported the health, voluntary and social care services received over the last four 
weeks at baseline and at the assessment visit for day 28 .[76 ] 
Economic Evaluation
The economic evaluation component of this trial aims to test the feasibility of collecting cost 
data, with modified CSRI, and quality of life data, with EQ-5D-5L. We will develop the tailored 
CSRI questionnaire, considering patient understanding and care settings. It will be ideal to 
collect cost data by formal health care, social care and informer care separately. We will 
identify difficulties answering CSRI questions, if any, by checking item response rate and 
reading free text answers to open-ended questions. 
We will calculate the summary statistics of formal and informal care costs (and social care 
costs, if possible) for the last four weeks at baseline and at the assessment visit for day 28. 
Finally we will examine the possibility of assessing the cost-effectiveness using outcome 
measurements (average breathlessness severity measured by NRS for breathlessness, 
breathlessness mastery measured by CRQ and IPOS and Quality Adjusted Life Years 
(QALYs) derived from using EQ-5D-5L) at 4 weeks. We will explore if it is possible to produce 
a cost-effectiveness plane with the results from the cost-effectiveness analysis.  
xxxiv Permission to use obtained from the Cicely Saunders Institute.
xxxv HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994.Record form items originally published in 
Acta Psychiatrica Scandinavica 67, 361–70, copyright © Munksgaard International Publishers Ltd, Copenhagen, 
1983.This edition first published in 1994 by nferNelson Publishing Company Ltd (now GLAssessment Ltd),389 
Chiswick High Road, London W4 4AL GL Assessment Ltd is part of the Granada Learning Group.
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Endpoints
1.20 Primary Endpoint
The primary endpoint is the number of patients recruited across 3 hospitals over a 12-month 
period. This has been chosen to determine whether a larger scale trial of the same design is 
feasible, when expanded to additional centres [82]. The decision to proceed to a future without 
further amendments will be based on the ability to recruit an average of 5 patients per month 
within a 12-month period (e.g. approximately 60 patients). 
1.21 Secondary Endpoints
1.21.1 Feasibility 
Other outcome measures of feasibility will be assessed to determine whether the design of the 
future large-scale trial may need to be adapted to improve recruitment or reduce attrition. 
Physical activity and toxicity outcomes will be used to inform the design of the future trial, 
however they will not be used to inform the decision as to whether or not to proceed to a future 
large-scale trial. These are:
 Number of patients screened for eligibility and reasons for non-eligibility
 Proportion of eligible patients randomised and reasons for non-randomisation
 Proportion of participants for which blinding is maintained
 Proportion of research assessors for which blinding is maintained
 Proportion of participants remaining on study for 28 days
 Proportion of, and reasons for, participants with missing data for trial outcomes
 Proportion of participants who would be eligible for dose escalation at 28 days
 Treatment compliance over the period
Feasibility outcome measures relating to recruitment will be assessed by the use of screening 
logs completed at each site. 
Blinding will be assessed using the Bang Blinding index [83]. 
Missing data and study compliance will be assessed based on completed and received CRFs, 
summarised for each trial outcome measure [84]. 
Eligibility for dose escalation will be assessed based on breathlessness intensity at day 28 and 
tolerability of treatment.
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1.21.2 Activity
 Key Activity endpoint: severity of breathlessness at the assessment visit for day 28 as 
assessed by the NRS (“at worst” severity of breathlessness over the last 24 hours). 
 Severity of breathlessness at the assessment visits/calls for days 7, 14 and 21, as 
assessed by NRS (average and “at worst” severity of breathlessness as assessed over 
the last 24 hours).
 Lower extremity functioning as assessed by the Short Physical Performance Battery 
(SPPB) [66] at the assessment visit for day 28.
 Opioid medication: at the assessment visits/calls for days 7, 14, 21 and 28.
1.21.3 Safety and Toxicity
 Adverse events, using the Common Terminology Criteria for Adverse Events (CTCAE) 
categorisation (v4) [69] as reported at the assessment visits/calls for days 7, 14, 21 and 
28.
 Safety will be reported based on the occurrence of SAEs, SARs and SUSARs.
 Australia-modified Karnofsky Performance Status (AKPS) and modified Medical 
Research Council (mMRC) dyspnoea scale at the assessment visits for days 14 and 28. 
1.21.4 Symptoms and Quality of Life
 Coping self-belief assessment as assessed by the General Self-Efficacy Scale (GSES) at 
the assessment visit for day 28.
 Mobility, self-care, usual activities, pain/discomfort and anxiety/depression as assessed 
by EQ-5D-5L at the assessment visit for day 28.
 Palliative symptoms as assessed by the Integrated Palliative care Outcome Scale (IPOS) 
at the assessment visits for days 14 and 28.
 Anxiety and depression as assessed by the Hospital Anxiety and Depression Scale 
(HADS) at the assessment visits for days 14 and 28.
 QoL as assessed by Chronic Respiratory Questionnaire (CRQ) at the assessment visits 
for days 14 and 28.
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Statistical Considerations
Sample size and planned recruitment rates
As the trial is designed to assess the feasibility of conducting a future definitive large-scale 
trial, a formal power calculation is not considered appropriate as effectiveness is not being 
formally evaluated.
The future large-scale trial would be designed to detect a minimum clinically important effect 
size of 0.5 in NRS (or a 1 point change) [2, 25]. With 90% power testing at the 5% two-sided 
significance level, approximately 90 participants per arm would be required. This sample size 
calculation will be revisited based on the observed variability of the primary outcome in this 
feasibility trial. It is expected that attrition rates will be approximately 20%, however this will be 
assessed within this feasibility trial. Assuming a 20% attrition rate, the future trial would require 
approximately 230 participants in total.
Feasibility of recruitment to a future large-scale trial of the same design will be concluded if 
the trial is able to recruit an average of 5 patients per month over a 12-month period, equivalent 
to approximately 60 patients, based on 3 recruiting sites. This equates to 1-2 patients per 
month, per site. The sites taking part in the feasibility trial are representative of those sites 
which would be involved in the future larger trial. Assuming 11 sites open to recruitment in the 
future trial, recruiting 1-2 patients per month each, this would mean a 230-participant trial 
would be expected to recruit in approximately 18 months to allow for the setup and initiation 
of all sites.
For this feasibility trial we plan to recruit approximately 60 patients in total (i.e. 30 patients to 
each treatment arm) from 3 sites in the UK over a 12-month period. Guidance on pilot study 
design by Browne et al [85, 86] state that at least 30 patients should be included to estimate a 
parameter for future sample size calculation [86]. In order to estimate the expected variability of 
the future large-scale trial’s primary outcome measure of breathlessness (“at worst”) at day 28 
in the mirtazapine arm, 30 participants are required. As the future trial will be randomised, this 
equates to a total of 60 participants required, with 1:1 randomisation.
Statistical Analysis
1.22 General Considerations
Statistical analysis of the main feasibility trial is the responsibility of the CTRU Statisticians. 
The analysis plan outlined in this section gives a brief description of the statistical analyses 
which will be carried out at the end of recruitment and trial follow-up. A final, more detailed, 
statistical analysis plan will be written before any analysis is undertaken. Given that this is a 
feasibility trial, the analysis will require descriptive statistics rather than any formal hypothesis 
testing.
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Baseline characteristics of patients will be summarised.
Qualitative and Health Economics analyses will be the responsibility of the qualitative 
researcher and health economist respectively.
1.23 Analysis populations
The primary endpoint analysis will be based on the population of participants randomised 
within the 12-month recruitment period. 
Endpoints which relate to data collected prior to randomisation will be analysed using all 
patients approached for entry to the study.
Analyses of safety data will be carried out on the safety population, defined as those 
participants receiving at least one dose of trial treatment, and will summarise participants 
according to the treatment actually received. 
The remaining analysis will be carried out on the intention-to-treat (ITT) population defined as 
all participants randomised to the trial, regardless of adherence to the protocol, withdrawal of 
consent or losses to follow-up. Participants will be included within the treatment arm to which 
they were randomised.
1.24 Frequency of analysis
There are no formal analyses planned until after the trial is closed to recruitment. The analysis 
of the primary endpoint and all secondary endpoints will take place when all participants have 
been followed up for safety, i.e. 7 days after last trial treatment dose. 
A Trial Steering Committee (TSC) will be set up to independently review data on safety, 
protocol adherence and recruitment. The TSC will review safety data for all participants 
entered into the trial approximately 6 months into recruitment (or as deemed appropriate by 
the TSC). Interim reports containing safety data, protocol adherence and recruitment will be 
presented to the TSC in strict confidence. 
1.25 Primary Endpoint Analysis
The average number of patients recruited per month across 3 trial sites over a 12-month period 
will be summarised, overall and by trial site. The total number of patients recruited will be 
summarised by month, overall and by trial site. 
Summaries will be presented overall by treatment arm, and by recruitment setting and 
diagnosis.
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1.26 Secondary Endpoint Analysis
1.26.1 Feasibility
The number of approaches to patients and randomisations in total throughout the 
randomisation period and per month will be summarised overall and by recruitment setting and 
diagnosis. The proportion of screened patients who are eligible for randomisation will be 
presented with corresponding 95% confidence intervals. Reasons for non-eligibility will be 
summarised. The proportion of eligible patients who are randomised will be presented with 
corresponding 95% confidence intervals. Reasons for non-randomisation will be summarised. 
The proportion of participants for whom blinding is maintained will be summarised overall and 
by treatment arm, and also by recruitment setting and diagnosis, with corresponding 95% 
confidence intervals. The proportion of participants who became unblinded and the reasons 
for unblinding will also be presented. The blinding index for each arm will be calculated using 
the bang blinding method along with 95% confidence interval. The blinding index calculates 
the difference between the proportion of correct and incorrect “guesses”. The blinding index 
takes values between -1 and 1. 
The proportion of participants who remain on study for 28 days, will be summarised overall 
and by treatment arm, and also by recruitment setting and diagnosis, with corresponding 95% 
confidence intervals. The proportion of participants who stop treatment early and the reasons 
for stopping treatment will be presented.
The proportion of participants who would be eligible for dose escalation at 28 days, will be 
summarised overall and by treatment arm, and also by recruitment setting and diagnosis, with 
corresponding 95% confidence intervals. Those participants who would have not been eligible 
for dose escalation will be summarised along with the reason why they were not eligible for 
dose escalation. 
The proportion of participants with missing data for each trial outcome separately will be 
summarised overall and by arm, at each time point of assessment. Where available, reasons 
for missing data will be provided. 
Treatment compliance will be summarised by the proportion of participants with dose 
reductions or omissions and total number of missed doses, by treatment arm. Reasons for 
dose reductions or omissions will also be presented.
Qualitative data will be analysed by the qualitative researcher. A separate analysis plan will 
be written outlining the proposed analysis.
Health Economic data will be analysed by the Health Economics researcher. A separate 
analysis plan will be written outlining the proposed analysis.
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1.26.2 Activity
Descriptive summaries of average severity of breathlessness over the last 24 hours and at 
worst, as assessed by NRS score, will be presented overall and by arm at each time point 
(baseline, days 7, 14, 21 and 28). Change in average and worst 24 hour breathlessness NRS 
score from baseline will also be presented with corresponding 95% confidence intervals. 
Average and worst breathlessness/24 hours will also be presented graphically using line 
graphs.
Differences in average and worst breathlessness/24 hours at day 28 between arms will be 
estimated using multi-level repeated measures modelling adjusting for NRS score at baseline, 
days 7, 14 and 21, and for minimisation factors, and incorporating time, treatment, and 
treatment by time interaction terms. Covariate estimates will be presented with corresponding 
standard errors. Treatment effect size (change in average and worst breathlessness) will be 
presented with corresponding 95% confidence intervals.
Mean Chronic Respiratory Questionnaire (CRQ) total score will be summarised with 
corresponding 95% confidence intervals and presented by treatment arm for baseline, days 
14 and 28 by treatment arm. Mean change from baseline will also be summarised.   
Mean lower extremity functioning, measured by the Short Physical Performance Battery 
(SPPB) at baseline and on day 28 will be summarised with corresponding 95% confidence 
intervals and presented by treatment arm. Mean change from baseline will also be 
summarised.
Opioid medication
The proportion of participants receiving opioid medication at each visit (days 7, 14, 21 and 28) 
will be summarised along with the type of medication by treatment arm.
1.26.3 Safety and Toxicity
The number of SAEs, SARs and SUSARs will be summarised descriptively by arm, by 
causality, seriousness, and body system. 
The proportion of participants experiencing each toxicity will be summarised by maximum NCI 
CTCAE grade experienced over 28 days, by treatment arm. 
The change in AKPS and mMRC from baseline to day 14 and 28 will be summarised. 
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1.26.4 Quality of Life and Patient-reported outcomes
The percentage of non-responders and missing data will be summarised for each 
measurement and time-point, overall, by treatment arm and will include the proportion of 
expected patient-completed questionnaire packs that are missing, the proportion with missing 
questionnaires from each pack, the proportion of questionnaires with missing item level data, 
the number of missing items on each questionnaire and the number of missing scores due to 
missing individual question responses (items). 
Outcome measures relating to Quality of Life and patient-reported outcomes (GSES, EQ-5D-
5L, IPOS, HADS) will be summarised by point estimates and 95% confidence intervals and 
presented by treatment arm, at each time point collected. 
The mean score of the GSES will be presented by treatment arm along with standard 
deviations and 95% confidence intervals. The change in mean score from baseline to day 28 
will also be presented. 
The proprtion of particiapants reporting each level of percieved problems will be presented for 
the EQ-5D-5L by domain and treatment arm for day 28.
The mean IPOS score will be presented overall and for each domain by treatment arm along 
with 95% confidence intervals for each visit.
HADS scores will be calculated for each patient and the proportion of participants in each level 
of Anxiety and Depression will be presented by treatment arm for day 28.
Trial Monitoring
1.27 Trial Steering Committee
A Trial Monitoring Plan will be developed and agreed by the Trial Management Group (TMG) 
and Trial Steering Committee (TSC) based on the trial risk assessment; this will include on site 
monitoring by Sponsor.
The independent TSC will review the safety and ethics of the study. Detailed un-blinded reports 
will be prepared by the CTRU for the TSC approximately 6 months into recruitment, and then 
at the end of recruitment. The TSC will be provided with detailed unblinded reports containing 
the information agreed in the data monitoring analysis plan. 
Any unblinded interim reports provided to the TSC will be provided by the CTRU Trial 
Statistician for consideration in a closed session and the reports will be securely password-
protected.
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1.28 Data Monitoring
Due to the feasibility nature of this trial, which has no planned interim analyses or review of 
activity data, a separate Data Monitoring & Ethics Committee (DMEC) has not been 
established. Independent data and ethical monitoring activities will be conducted by the TSC 
as described above. For any subsequent future large-scale trial however, both a DMEC and a 
TSC would be established.
Data will be monitored for quality and completeness by the CTRU. Missing data will be chased 
until it is received, confirmed as not available, or the trial is at analysis. However, missing data 
items will not be chased from participants.  The Investigator(s) will permit trial-related 
monitoring, audits, REC review, and regulatory inspections by providing Sponsor, Regulators 
and REC direct access to source data and other documents (e.g. patients’ case sheets, blood 
test reports, X-ray reports, histology reports etc.).
1.29 Clinical Governance Issues
To ensure responsibility and accountability for the overall quality of care received by 
participants during the study period, clinical governance issues pertaining to all aspects of 
routine management will be brought to the attention of the TSC and, where applicable, to 
individual NHS Trusts.
Quality Assurance, Ethical and Regulatory 
Considerations
1.30 Quality Assurance
Monitoring of this trial will be to ensure compliance with GCP and scientific integrity will be 
managed and oversight retained, by the Sponsor Quality Team.
1.31 Serious Breaches
CTRU and Sponsor have systems in place to ensure that serious breaches of GCP or the trial 
protocol are picked up and reported. Investigators are required to promptly notify the CTRU of 
a serious breach (as defined in Regulation 29A of the Medicines for Human Use (Clinical Trials) 
Regulations 2004 and amendments) that they become aware of. A ‘serious breach’ is a breach 
which is likely to effect to a significant degree – 
(a) the safety or physical or mental integrity of the subjects of the trial; or
(b) the scientific value of the trial.
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In the event of doubt or for further information, the Investigator should contact the Senior Trial 
Co-ordinator at the CTRU.
1.32 Ethical and Regulatory Considerations
The trial will be conducted in compliance with the principles of the Declaration of Helsinki 
(1996), the principles of GCP and in accordance with all applicable regulatory requirements 
including but not limited to the NHS Research Governance Framework and the Medicines for 
Human Use (Clinical Trial) Regulations 2004, as amended in 2006 and any subsequent 
amendments. Informed written consent will be obtained from the patients prior to 
randomisation into the trial. The right of a patient to refuse participation without giving reasons 
must be respected. The participant must remain free to withdraw at any time from the trial 
without giving reasons and without prejudicing his/her further treatment. The study will be 
submitted to and approved by a REC, the MHRA for Clinical Trial Authorisation and the 
appropriate Site Specific Assessor for each participating trial site prior to entering patients into 
the trial. The CTRU will provide the REC with a copy of the final protocol, patient information 
sheets, consent forms and all other relevant study documentation.
The Chief Investigator will submit a final report at conclusion of the trial to the Sponsor and the 
REC, and the Sponsor will upload this report to the EudraCT website and notify the MHRA, 
within the timelines defined in the Regulations.
Confidentiality
All information collected during the course of the trial will be kept strictly confidential. 
Information will be held securely on paper and electronically at the CTRU and at Sponsor 
offices. The CTRU and Sponsor will comply with all aspects of the 1998 Data Protection Act 
and operationally this will include:
 consent from participants to record personal details including name, date of birth 
and NHS number;
 appropriate storage, restricted access and disposal arrangements for participant 
personal and clinical details;
 consent from participants for access to their medical records by responsible 
individuals from the research staff, Sponsor or from regulatory authorities, where it 
is relevant to trial participation;
 consent from participants for the data collected for the trial to be used to evaluate 
safety and develop new research;
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 participant name will be collected when a participant is randomised into the trial but 
all other data collection forms that are transferred to or from the CTRU or Sponsor 
will be coded with a trial number and will include two participant identifiers, usually 
the participant’s initials and date of birth;
 where central monitoring of source documents by CTRU or Sponsor  (or copies of 
source documents) is required (such as scans or local blood results), the 
participant’s name must be obliterated by site before sending;
 where anonymisation of documentation is required, sites are responsible for 
ensuring only the instructed identifiers are present before sending to CTRU or 
Sponsor.
If a participant withdraws consent from further trial treatment and / or further collection of data 
their data collected to date will remain on file and will be included in the final study analysis.
Most CRFs will be sent to the CTRU via normal Royal Mail post, however for CRFs which need 
expediting to the CTRU (SAE, SAR, Death, Notification of Pregnancy, End of Trial Treatment 
CRFs), these must be sent either by fax or by secure encrypted electronic transfer.
For patients who take part in the Qualitative sub-study (see Appendix D), their data related to 
this sub-study will include audio-recordings of their interviews. This data will be collected from 
trial sites by the Qualitative sub-study Researcher and held at the Cicely Saunders Institute 
(King’s College London). All data (paper and electronic) will be held securely and in 
accordance with the 1998 Data Protection Act.
Archiving
At the end of this trial, all trial data will be stored in line with the Medicines for Human Use 
(Clinical Trials) Amended Regulations 2006 and the Data Protection Act and archived in line 
with the Medicines for Human Use (Clinical Trials) Amended Regulations 2006 as defined in 
the Sponsor Archiving Standard Operating Procedure (SOP). Data held by the CTRU will be 
archived in the Leeds archive facility and site data and documents will be archived at the 
participating sites. Data held by Sponsor (on behalf of the Sponsors) on the main trial, and all 
Qualitative Interview data associated with the sub-study will be archived in a dedicated archive 
facility as designated by Sponsor. Following authorisation from Sponsor, arrangements for 
confidential destruction will then be made.
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Statement of Indemnity
The trial is sponsored by King’s College London and King’s College London NHS Foundation 
Trust. The Sponsors will at all times maintain adequate insurance in relation to the study 
independently. King’s College London, through its own professional indemnity (Clinical Trials) 
and no fault compensation and the Trust having duty of care to patients via NHS indemnity 
cover, in respect of any claims arising as a result of clinical negligence by its employees, 
brought by or on behalf of a study patient. 
Study Organisational Structure
1.33 Individuals and Individual Organisations 
Chief Investigator (CI) – The CI is involved in the design, conduct, co-ordination and 
management of the trial. The CI will have overall responsibility for the design and set-up of the 
trial, the investigational drug supply and pharmacovigilance within the trial. 
Trial Sponsor –is responsible for site monitoring, submissions to the MHRA and trial initiation 
management and financing of the trial as defined by Directive 2001/20/EC. 
Clinical Trials Research Unit (CTRU) – The CTRU will have responsibility for conduct of the 
trial as delegated by Sponsor in accordance with relevant GCP standards and CTRU SOPs. 
The CTRU will provide set-up and monitoring of trial conduct to CTRU SOPs, and the GCP 
Conditions and Principles as detailed in the UK Medicines for Human Use (Clinical Trials) 
Regulations 2006 including, randomisation design and service, database development and 
provision, safety management and reporting, protocol development, CRF design, trial design 
and statistical analysis (excluding qualitative interview and health economic analyses) for the 
trial. In addition the CTRU will support REC, Site Specific Assessment and NHS Permissions 
submissions and clinical set-up, ongoing management including training and promotion of the 
trial. The CTRU will be responsible for the day-to-day running of the trial including trial 
administration, database administrative functions, data management and the main statistical 
analysis.
Central Research Nurse – The Central Research Nurse will provide support to site research 
nurses.
Central pharmacy – The Central pharmacy will have responsibility for trial IMP manufacture, 
labelling and distribution to trial sites.
Qualitative Sub-study Researcher – The Qualitative Sub-study Researcher will have 
responsibility for the conduct of the qualitative interview sub-study. Duties will include the 
training and supervision of site research teams involved in the interviews, and collection and 
analysis of the sub-study data.
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Health Economist – The Health Economist will have responsibility for the analysis of the 
health economy data (EQ-5D-5L and CSRI).
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1.34 Oversight and Trial Monitoring Groups
Trial Management Group (TMG) – The TMG, comprising the CI, Sponsor representative(s), 
CTRU team, other key external members of staff involved in the trial and a nursing 
representative will be assigned responsibility for the clinical set-up, ongoing management, 
promotion of the trial, and for the interpretation and publishing of the results. Specifically the 
TMG will be responsible for (i) protocol completion, (ii) CRF development, (iii) obtaining 
approval from the REC and supporting applications for Site Specific Assessments, (iv) 
submitting a Clinical Trial Authorisation (CTA) and obtaining approval from the MHRA, (v) 
completing cost estimates and project initiation, (vi) nominating members and facilitating the 
TSC, (vii) reporting of serious adverse events, (viii) monitoring of screening, recruitment, 
treatment and follow-up procedures, (ix) auditing consent procedures, data collection, trial end-
point validation and database development.
Trial Steering Committee (TSC) – The TSC will provide overall supervision of the trial, in 
particular trial progress, adherence to protocol, participant safety and consideration of new 
information. It will include an Independent Chair, not less than two other independent members 
and a consumer representative. The CI and other members of the TMG may attend the TSC 
meetings and present and report progress. It is planned that this committee will meet before 
the trial opens to recruitment, 6 months int  the recruitment period, and then again after the 
end of trial recruitment.
Publication Policy
The trial will be registered with an authorised registry, according to the International Committee 
of Medical Journal Editors (ICMJE) Guidelines, prior the start of recruitment. 
The success of the trial depends upon the collaboration of all participants. For this reason, 
credit for the main results will be given to all those who have collaborated in the trial, through 
authorship and contributorship. Uniform requirements for authorship for manuscripts submitted 
to medical journals will guide authorship decisions. These state that authorship credit should 
be based only on substantial contribution to: 
 conception and design, or acquisition of data, or analysis and interpretation of data,
 drafting the article or revising it critically for important intellectual content,
 and final approval of the version to be published,
 and that all these conditions must be met (www.icmje.org).
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In light of this, the CI, key clinical advisors and relevant senior CTRU staff will be named as 
authors in any publication. In addition, all collaborators will be listed as contributors for the 
main trial publication, giving details of roles in planning, conducting and reporting the trial.
To maintain the scientific integrity of the trial, data will not be released prior to the first 
publication of the analysis of the primary endpoint, either for trial publication or oral 
presentation purposes, without the permission of the TSC. In addition, individual collaborators 
must not publish data concerning their participants which is directly relevant to the questions 
posed in the trial until the first publication of the analysis of the primary endpoint.
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Appendix A: Modified Medical Research Council 
(mMRC) Dyspnoea Scale
This is the modified Medical Research Council (mMRC) scale36 that uses the same descriptors 
as the original MRC scale, in which the descriptors are numbered 1-5. The modified MRC 
scale (0-4) is used for calculation of BODE (Body mass index, airflow Obstruction, Dyspnoea 
and Exercise capacity) index.
Grade
0 “I only get breathless with strenuous exercise”
1 “I get short of breath when hurrying on the level or walking up a slight hill”
2 “I walk slower than people of the same age on the level because of breathlessness or 
have to stop for breath when walking at my own pace on the level”
3 “I stop for breath after walking about 100 yards or after a few minutes on the level”
4 “I am too breathless to leave the house” or “I am breathless when dressing”
36 Dennis E. Doherty, MD, FCCP, Mark H. Belfer, DO, FAAFP, Stephen A. Brunton, MD Leonard Fromer, MD, 
Charlene M. Morris, MPAS, PA-C, Thomas C. Snader, PharmD, CGP, FASCP. Chronic Obstructive Pulmonary 
Disease: Consensus Recommendations for Early Diagnosis and Treatment. Journal of Family Practice, 
November, 2006.
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Appendix B: Australia-modified Karnofsky 
Performance Scale (AKPS)
The Australia-modified Karnofsky Performance Scale (AKPS)37 is a measure of the patient’s 
overall performance status or ability to perform their activities of daily living. It is a single score 
between 10 and 100 assigned by a clinician based on observations of a patient’s ability to 
perform common tasks relating to activity, work and self-care. A score of 100 signifies normal 
physical abilities with no evidence of disease. Decreasing numbers indicate a reduced 
performance status. The rating should be recorded as assessed (scores in increments of 10); 
in between scores such as 45, 55 or scores such as 50-60 are invalid.
Here are some examples of questions you might ask the potential participant in order to assess 
their AKPS score:
 “Have there been any changes today with your ability to attend to activities of daily 
living?”
 “Are you requiring more physical care today?”
 “How much time are you actually spending in bed?”
AKPS Assessment Criteria Score
Normal; no complaints; no evidence of disease 100
Able to carry on normal activity; minor sign of symptoms of disease 90
Normal activity with effort; some signs or symptoms of disease 80
Cares for self; unable to carry on normal activity or to do active work 70
Able to care for most needs; but requires occasional assistance 60
Considerable assistance and frequent medical care required 50
In bed more than 50% of the time 40
Almost completely bedfast 30
Totally bedfast and requiring extensive nursing care by professionals and/or family 20
Comatose or barely rousable 10
Dead 0
37 Abernethy, A. P., Shelby-James, T., Fazekas, B. S., Woods, D. Currow, D. C. (2005). The Australia-modified 
Karnofsky Performance Status (AKPS) Scale: A Revised Scale for Contemporary Palliative Care Clinical Practice 
[Electronic Version]. BioMed Central Palliative Care, 4, 1-12
Page 91 of 106
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplement Page 76          Higginson et al, Mixed-methods feasibility trial of mirtazapine for severe breathlessness
Appendix C: New York Heart Association (NYHA)
Doctors usually classify patients' heart failure according to the severity of their symptoms. The 
table below describes the most commonly used classification system, the New York Heart 
Association (NYHA) Functional Classification38. It places patients in one of four categories 
based on how much they are limited during physical activity.
Class Patient Symptoms
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.  If any physical activity is undertaken, discomfort increases.
38 http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-
Failure_UCM_306328_Article.jsp; accessed on 08/10/2015.
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Appendix D: Qualitative Sub-study
1.35 Background
A qualitative sub-study will run alongside the BETTER-B Feasibility trial to explore participants’ 
views of the trial, aspects that affect their willingness to participate and remain in the trial, and 
views of the most common effects of the treatment. This sub-study will involve qualitative 
interviews held with a purposively selected sample of 12-15 patients.
This sub-study will be conducted by research nurses at the participating trial sites and 
supported by the BETTER-B Research Associate based at Kings College London, under the 
supervision of the Chief Investigator Prof Higginson. 
Patients may feel uncomfortable with the use of a placebo-control, or the randomisation 
process. Understanding why patients choose not to participate or do not take up their 
treatment allocation will be crucial demonstrating that recruiting to a larger scale trial is 
feasible. We will explore what patients understand, perceive and feel about, how the BETTER-
B trial was presented to them and their expectations of trial burden. We will include those 
participants who have declined participation; those who agreed to participate in the trial but 
do not take up their treatment allocation after being randomised into a particular trial arm, and 
those who agree to take part. Recruitment and retention of participants is essential to 
demonstrate our ability to perform a definitive trial in this setting, and so this work will explore 
the factors influencing recruitment from the patients’ perspective. 
1.36 Aim
To qualitatively explore patient acceptability of the trial and recruitment processes to assist in 
optimisation of recruitment and follow-up strategies employed for a future large-
scalerandomised controlled trial.
Objectives
 To explore patients’ reasons for acceptance or refusal to participate in the BETTER-B 
trial
 To determine ways in which the BETTER-B trial can be improved
 To explore participants’ views of the placebo-control
 To explore participants’ views of the randomisation process
 To identify methods and measures to be used to help generate specific 
recommendations for improvement
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1.37 Patient Interview Eligibility Criteria
Patient Inclusion Criteria
1. Approached to consider entry into the BETTER-B Feasibility trial and either:
 Agreed to participate in the trial; or
 Decided against participation after randomisation; or
 Decided against participation when study presented to them.
2. Willing and able to comply with requirements of this sub-study
3. Written informed consent obtained to participate in this sub-study
Patient Exclusion criteria
1. Decline participation in this sub-study
2. Unable to comply with requirements of this sub-study protocol 
1.38 Sampling
We will conduct qualitative interviews with up to 15 patients (subject to data saturation).  We 
will aim to include diverse experiences, including patients (or their families if the patients are 
not available) who consent and (where possible) do not consent to trial enrolment, completers 
and non-completers, across patients with different diseases (cancer, heart failure, COPD), 
different ages and ethnic groups. This sub-study will be open to patients from all BETTER-B 
trial sites. 
Interviews will be collected after the end of the participation for patients who complete, or after 
non-consent or withdrawal (where ethically feasible).
1.39 Consent Process
Approaching patients who have consented to the main BETTER-B Feasibility trial
Patients who consent to the main BETTER-B Feasibility trial will be asked if they would be 
happy to be approached about this sub-study at the time of consent into the main trial – this 
is an optional consent item on the main trial’s Informed Consent Form (ICF). 
Approaching patients who have declined to the main BETTER-B Feasibility trial
Patients who decline to participate in the main BETTER-B Feasibility trial will be provided with 
a BETTER-B Feedback Questionnaire at the time of refusal. The last question on this 
questionnaire is about the qualitative sub-study and patients can indicate whether or not they 
would like to be approached about the sub-study. This questionnaire is entirely optional 
however, so we anticipate that some patients will complete this and therefore be able to 
indicate their willingness to know more about the sub-study, whereas other patients will not 
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wish to complete the questionnaire, but may still be willing to speak to a research nurse as 
part of this sub-study.  
For those patients who decline to participate in the main trial and agree to complete the 
BETTER-B Feedback Questionnaire, they can indicate that they would be happy to be 
approached about this qualitative sub-study by answering the last question on the Feedback 
Questionnaire.   
For those patients who decline to participate in the main trial and also decline to complete the 
BETTER-B Feedback Questionnaire, they will be asked at the time of refusal if they would be 
happy to be approached about this qualitative sub-study. 
Consent to the qualitative sub-study
Those who do consent to be approached regarding the qualitative sub-study will be contacted 
by a member of their trial site’s BETTER-B research team who will briefly describe this sub-
study, go over its objectives, and answer any questions. The patient will also be provided with 
a sub-study Participant Information Sheet (PIS) and ICF. If patients give their consent to be 
interviewed, suitable arrangements will be made. The interview will be conducted at a time 
and place agreeable to the patient – this may be in the patient’s home, or other location of 
their choice. 
If patients change their mind following consent, they can withdraw from the sub-study at any 
time (including during the conduct of the interview). In these cases, no further contact will be 
made by the qualitative research team.  
If the patient requires more time for consideration, they may contact their trial site’s research 
team at a later time and arrange an interview.
1.40 Interview Procedure
Since several studies [87, 88] have pointed out that there are no major differences in the results 
of telephone and face-to-face interviews, the participants will be invited to be interviewed either 
over the phone or in person, to accommodate family and professional obligations. We selected 
this recruitment strategy because research shows that on one hand there is no evidence that 
potential participants object to such a system, while on the other hand such an approach 
minimises response bias and potentially increases the methodological rigour of the research 
[89].
Interviews will be audio-recorded and interviews are expected to last 30 to 45 minutes. 
Interviewers will follow a topic guide and probe specifically in areas of interest, including: why 
they agreed to participate or not, what might increase or reduce this, views of placebo control 
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arm, frequency of follow up interviews, best mode of contact, views of the trial, views of method 
and location of interviews, view of methods of data collection. The research nurses will be 
trained by the Qualitative sub-study Researcher (based at King’s College London) in the 
conduct of these qualitative interviews, and the Researcher will monitor the quality of the 
interviews and will conduct the analysis.
The research nurses will be supported in the conduct of the qualitative interviews by the 
Researcher under the supervision of Prof Higginson. Qualitative data will be transcribed as 
soon as it is received, and prepared for analysis. The Researcher will monitor the progress of 
qualitative interviews and recruitment of the sub-sample according to the matrix and identify 
and follow up on any aspects that need to be explored further. Qualitative interviews will be 
completed by the end of the BETTER-B Feasibility trial’s recruitment period to allow adequate 
time for analysis and integration.
1.41 Data analysis
The qualitative data will be audio recorded, transcribed verbatim and analysed following the 
framework method established by Ritchie and Spencer to identify key themes. The framework 
matrix will be developed using NVivo 10 software (QSR) and incorporate the interview topic 
guide, ideas from the existing literature [90-94] and prominent themes identified from a 
preliminary review of the transcripts. The transcripts will be coded line by line and additional 
themes entered into the matrix where necessary. The matrix will then be populated with 
summarised data according to participant and theme, and used to identify common and 
divergent issues.
1.42 Endpoints
Issues related to trial design and conduct that may be responsible for poor recruitment will be 
discussed with the research team to inform recruitment for the definitive trial. This may include 
re-design of study information, recruitment strategy, advice about presenting the study, or 
discussions about equipoise.
Feedback relating to the importance and timing of candidate primary and secondary endpoints 
and the acceptability of and feasibility of intervention blinding will be provided to the research 
team to inform any subsequent large-scale trial.
1.43 Ethical Considerations 
“Lone worker” policy 
Interviews are being conducted on a one-to-one basis between a participant and the research 
nurse. As the participants can choose the time and place of the interview and can opt to be 
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interviewed in their own homes, there is some risk to the research nurse. For this reason the 
research teams will follow their local “lone worker” policies. 
Potential distress
Recent evidence suggests that qualitative interviewing, even when using unstructured 
interview guides (i.e. those which are not pre-approved by the ethics committees) does not 
have long-term negative effect which would require psychological treatment. In fact, the 
participants are far more likely to experience relief after discussing distressing experiences [95]. 
However, it is nevertheless possible that the participant will experience distress while 
remembering the nature of their illness. To address this issue we will make sure that the 
researcher working on the sub-study will have considerable experience in qualitative research 
in healthcare and working with vulnerable patient populations and (s)he will be able to handle 
these issues sensitively. 
If the researcher is not able to address participant’s distress then they will follow their local 
“distress protocol” which may involve the patient being referred to the local recruiting site’s 
counselling service.
Distress may also be cause to the researcher themselves. Where this occurs, they should 
again follow the local “distress protocol”.
1.44 Confidentiality
All participants in this sub-study will sign Informed Consent Forms (ICFs) – these will be held 
securely at trial sites (copies will not be sent to the Qualitative sub-study Researcher at King’s 
College London). Sub-study participants will also have their interviews audio-recorded. This 
electronic data will be held securely at trial sites initially and then sent to King’s College London 
using encrypted electronic transfer, where the recordings will then be transcribed. All data 
(electronic and paper) will be held securely at King’s College London in accordance with the 
1998 Data Protection Act.  
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Online Box S1- Primary, secondary, clinical activity and 
other endpoints assessed in the BETTER-B trial
Primary endpoint = number of patients recruited across 3 hospitals over 12 months, target of 60 
patients. 
Secondary feasibility endpoints included: eligibility and recruitment rates in different settings, 
proportion of patients on trial at 28 days and proportion of patient with missing data, eligibility for 
dose escalation, and treatment compliance. 
Toxicity and safety was assessed by adverse events using the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) categorisation (v4), and serious adverse events. 
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-
29_QuickReference_8.5x11.pdf)
Blinding maintained: At day 28 participants ‘guessed’ their treatment arm, data used to calculate the 
Bang Blinding Index (BBI) (with the 95% confidence interval) to assess how successful blinding had 
been within the trial. 1  The BBI calculates the difference between the proportion of correct and 
incorrect “guesses” with values -1 to 1. A 0 as a null value indicates the most desirable situation under 
random blinding. A positive value may imply failure in blinding above random guessing (i.e. a majority 
of participants guess their treatment allocation correctly), and a negative value may suggest the 
success of blinding or failure of blinding in the other direction (i.e. more individuals mistakenly name 
the alternative treatment).
Clinical activity endpoints were: 
Primary - worst breathlessness previous 24 hours: “How bad has your breathlessness felt at its worst 
over the past 24 hours?”  Numerical Rating Scale (NRS) 0 (not breathless at all) – 10 (the worst possible 
breathlessness)  
Patients’ symptoms and quality of life (QoL) , average breathlessness previous 24 hours “How bad has 
your breathlessness felt on average over the past 24 hours?” NRS, 0 (not breathless at all) – 10 (the 
worst possible breathlessness), the Chronic Respiratory Questionnaire (CRQ) subscale scores, 
Integrated Palliative Care Outcome Scale (IPOS), Hospital Anxiety and Depression Scale, Generalised 
Self Efficacy Scale, EQ-5D-5L, and lower extremity functioning as assessed by the Short Physical 
Performance Battery (SPPB). As outlined in reference5 
Services received, costs, other treatments: Health, social and informal care use was recorded using the 
Client Services Receipt Inventory (CSRI). As outlined in reference5 
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Online Table S1 – Baseline demographic, clinical and 
minimisation characteristics
Numbers are n (%) unless indicated. 
 
Mirtazapine
n=30
Placebo
n=34
Age (years), Mean (s.d.) 72.9 (7.12) 70.6 (9.43)
Gender 
Men 24 (80.0%) 23 (67.6%)
Women 6 (20.0%) 11 (32.4%)
Main Diagnosis
Lung Disease & Cancer 2 (6.7%) 1 (2.9%)
Lung Disease & Chronic Heart Failure 0 (0.0%) 1 (2.9%)
Cancer 0 (0.0%) 1 (2.9%)
Lung Disease 27 (90.0%) 29 (85.3%)
Chronic Heart Failure 1 (3.3%) 2 (5.9%)
Lung Disease categories (includes lung disease + other diagnosis)     29 (96.7%)    31 (91.2%)
COPD           20 (69.0%)     20 (64.5%)
ILD          8 (27.6%)      11 (35.4%)
COPD & ILD          1 (3.4%)     0 (0.0%)
AKPS score, Mean (s.d.) 62.0 (9.15) 63.8 (8.88)
Breathlessness at worst over 24 hours NRS / 10, Mean (s.d.) 7.6 (1.25) 8.0 (1.73)
Breathlessness on average over 24 hours NRS / 10, Mean (s.d.) 5.4 (1.36) 5.0 (1.76)
mMRC grade
Grade 3 - breathless after walking ~90 metres/few minutes on level 
ground
12 (40.0%) 15 (44.1%)
Grade 4 - too breathless to leave the house or when dressing 18 (60.0%) 19 (55.9%)
HADS score
0-14 19 (63.3%) 21 (61.8%)
15 or above 11 (36.7%) 13 (38.2%)
IPOS score / 17 items, Mean (s.d.) 21.5 (8.61) 19.7 (7.23)
EQ-5D Index, Mean (s.d) 0.53 (0.05) 0.60 (0.03)
EQ-VAS, Mean (s.d) 54.3 (17.9) 53.8 (18.0)
Total health and social care costs in the previous 3 months (£), 
Mean (s.d)
2220 (577) 2007 (727)
Receiving opioid medication
Yes 11 (36.7%) 10 (29.4%)
No 19 (63.3%) 24 (70.6%)
Participant able to complete QoL measures 30 (100.0%) 34 (100.0%)
Help required to complete QoL and type
Questions read out to participant 15 (50.0%) 16 (47.1%)
Helped to complete answers 4 (13.3%) 2 (5.9%)
Other 2 (6.7%) 1 (2.9%)
Total needing help 21/30 (70.0%) 19/34(55.9%)
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 Online Table S2 – Screening outcomes by method and 
diagnosis, and screened to recruitment ratio
Setting screened randomised
screened to 
recruitment ratio mirtazapine placebo
outpatient 98 25 3.9 11 14
inpatient 35 4 8.8 3 1
community * 45 8 5.6 4 4
data base * 203 23 8.8 11 12
other 28 4 7.0 1 3
total 409 64 6.4 30 34
main disease
cancer 19 1 19.0 0 1
lung disease 366 56 6.5 27 29
CHF 15 3 5.0 1 2
cancer + lung 
disease 8 3 2.7 2 1
lung disease + 
CHF 1 1 1.0 0 1
total 409 64 6.4 30 34
* note that some of these patients had not yet received pulmonary rehabilitation, and so might not be 
considered on optimal treatment. They were waiting for it to be offered to them, and it was clear that they 
would not commence until after the trial (~5 weeks) had completed. There was variability in the availablity of 
pulmonary rehabilitation across our centres.
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Online Figure S1- Mean (95% confidence interval) 
breathlessness at average over 24 hours during the 28 
weeks of the study, by study arm
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Online Box S2- Qualitative data relating to analysis
Reasons for taking part
“I was approached by …  during one of my regular check-ups… and I’ve been having problems 
breathing and she recommended one or two things as a result of that, and then asked if I would 
be interested in taking part in this study.” (72 year old man, ILD)
“I took part in a previous study a few years ago, something different, and they’d asked me, cause 
they knew I suffer from COPD, asked me if I’d be interested.” (56 year old woman, COPD).
“Because, as I say, I took that much out of the system, over- you know, and I think its time to put 
something back into it, you know, and if, if my condition it won’t do me any good but it might help 
other people in the future, you know. So, my expectations are in the ways that it’ll help other 
people in the future, you know, by me taking a part in these trials, you know, yeah. ” (64 year old 
man, COPD)
“I was asked to take part, by the specialist… he’d been, looking after me with my problem and he 
suggested that I might like to take part.” (84 year old man, ILD)
Home visits enabled trial participation for those who may have otherwise been unable.
“I’d have been more reluctant to take part if I had had to go to the hospital.” (71 year old man, 
COPD) 
“It could’ve been, shall we say, uncomfortable, getting to the hospital and getting to the clinic, if 
that’s the word for it. Erm so it’s much easier from my perspective, to be seen at home” (72 year 
old man, ILD) 
Most participants considered the trial period of 28 days to be acceptable, 
“I thought that as it was also only over a 28-day period I thought yeah, I’d, I’d be quite happy to 
try.” (70 year old woman, ILD)
however one participant felt a slightly longer trial may be beneficial with regards to determining 
effect from the trial medication - 
“Some days you feel healthy and some days you don’t, and, the days that I feel healthy, when it’s 
only a month’s trial, it could be like, well is it the drug or isn’t it the drug.” (56 year old woman, 
COPD)
Concern re antidepressant
“That did worry me, cause I don’t think I’m a depressed person…you didn’t get a sheet with side 
effects, this is what it does, so you couldn’t actually, you just, I didn’t know what to expect. (72 
year old man, ILD).
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“It wasn’t a great deal of information about the actual drug, to be honest… perhaps a little more 
information about at the time, saying this is what the drug is and this is what, you know, its used 
for, it might help, I don’t know” (82 year old man, Chronic Heart Failure)
Qualitative data indicated that the trial medication was straight forward to administer.
“It was tablets and I took them every day as I was asked to, um we made a note of them in a chart 
to make sure I had taken them, it was no problem at all.” (84 year old man, ILD)
“They gave you lots of information at the beginning to say what the trial was about and, and how 
it would take part, length of time it will take part over, er, the number of tablets I would have to 
take, this was all I think about setting the base line and then I went away with the first lot of 
tablets” (62 year old man, COPD)
One participant did however comment on the colour and size of the capsule.
“It was bright red, which I found quite alarming- red is for danger isn’t it, but I think, perhaps a 
gentler colour could be used… It was quite a large tablet to take along with the rest of them.” (72 
year old man, ILD)
Acceptability of the questionnaires, ease of completion and whether they captured aspects 
important to the person 
 “Well they were quite straightforward you know… they asked about my fitness, about my 
breathing, about my activities … they were straight forward.” (70 year old man, COPD)
“It was based a lot on day to day things, and things that normally happened. And I think that’s a 
really good way of people judging how much an illness is, is affecting… that’s the sort of things 
that people like me would measure, and that’s why I think the questions were realistic.” (62 year 
old man, COPD)
The carer of one participant suggested that it could be helpful to assess impact both for the 
person taking the trial medication, but also for carers and those closely involved with that person. 
“Because what I see is not what he sees… there should be one for me, and one for him, and you 
should have this comparison of what the carer sees, and what the person sees” (Carer of 67 year 
old man, ILD)
Importance of good relationships and support for continued participation
“I saw the same nurse, yeah, she got her own case, and I saw the doctor in between, he checked 
you over for blood pressure and all that sort of stuff” (81 year old man, COPD)
“It was very well organised, yes, and you know, we, we had erm, information from the team and 
they were all great, we could always contact them if we had any problems” (82 year old man, 
Chronic Heart Failure)
“I felt quite safe on the trial because I was contacted every week, either with a visit, or you know, I 
had, 2 telephone calls I think and 2 visits” (70 year old woman, ILD)
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“I found that it .. was no trouble to do it at all, and that people, the people here were really good 
and helpful and I had a full, er, a medical before I started on the course, which was good, it eased 
my mind as far as that went, so, erm, yeah ….   I found it was easy to do and er, just take the 
tablets on the night, there was no .. no inconvenience at all” (74 year old woman, COPD)
 “You could talk about … your condition to them, and they didn’t look down on you. They looked 
at you and, you know, they knew what you was talking about and … what you was going through. 
You know, and I could relate to what they was er, speaking about you know, and yeah I found it 
very helpful in one way or another’” (64 year old man, COPD)
“I felt that was good, because it was reassuring to know that there was someone who was gonna, 
rather than me call them, they were gonna call and say, ‘are you alright’ as it were. I mean, they 
had your telephone numbers, so I could call, but it was nice to think, well, now I’ve been checked 
on, and you’re taking due care during the trial” (72 year old man ILD)
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Online Table S3. Missing data in the study. Categorised using the 
MORECare classification for missing data in palliative care studies, detailing whether item or 
missed questionnaire due to death or illness 
Questionnaire/
outcome
Base
line
MORECare
Classification
Day 
14
MORECare
Classification
Day 
28
MORECare
Classification
Average NRS 0/64 1/63 2 ADI 1/58 4 ADI, 2 ADD, 1AaR
Worst NRS 0/64 1/63 2 ADI 1/58 4 ADI, 2 ADD, 1AaR
CRQ dyspnoea 0/64 2/62 3 ADI, 1 
missed data 
item
1/58 4 ADI, 2 ADD, 1AaR
CRQ fatigue 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
CRQ emotional 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
CRQ mastery 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS total 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS pain 0/64 1/62 3 ADI 2/58 4 ADI, 2 ADD, 1AaR, 1 
missed data item
IPOS shortness of breath 1/64 1 missed data 
item
2/62 3 ADI, 1 
missed data 
item
1/58 4 ADI, 2 ADD, 1AaR
IPOS weakness/lack of 
energy
2/64 2 missed data 
item
2/62 3 ADI, 1 
missed data 
item
2/58 4 ADI, 2 ADD, 1AaR, 1 
missed data item
IPOS nausea 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS vomiting 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS poor appetite 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS constipation 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS sore or dry mouth 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS drowsiness 0/64 1/62 3 ADI 2/58 4 ADI, 2 ADD, 1AaR, 1 
missed data item
IPOS poor mobility 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS anxiety 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
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IPOS family or friend 
worried
0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS depressed 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS at peace 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS sharing feelings 1/64 1 missed data 
item
1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS problems addressed 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
IPOS enough information 0/64 2/62 3 ADI, 1 
missed data 
item
1/58 4 ADI, 2 ADD, 1AaR
HADS anxiety 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
HADS depression 0/64 1/62 3 ADI 1/58 4 ADI, 2 ADD, 1AaR
GSES Total 0/64 2/58 4 ADI, 2 ADD, 1AaR, 1 
missed data item
EQ5D mobility 0/64 1/58 4 ADI, 2 ADD, 1AaR
EQ5D self-care 0/64 1/58 4 ADI, 2 ADD, 1AaR
EQ5D usual activities 0/64 2/58 4 ADI, 2 ADD, 1AaR, 1 
missed data item
EQ5D pain 0/64 1/58 4 ADI, 2 ADD, 1AaR
EQ5D anxiety and 
depression
0/64 1/58 4 ADI, 2 ADD, 1AaR
EQ5D health score 0/64 1/58 4 ADI, 2 ADD, 1AaR
SPPB Chair stand 11/6
4
11 ADI 9/58 12 ADI, 2 ADD, 1 AaR
SPPB Balance 16/6
4
11 ADI, 5 
missing data 
item
15/58 12 ADI, 2 ADD, 1AaR, 
6 missing data items
SPB Gait 11/6
4
11 ADI 9/58 12 ADI, 2 ADD, 1AaR
SPPB Summary 16/6
4
11 ADI, 5 
missing data 
item
15/58 12 ADI, 2 ADD, 1AaR, 
6 missing data items
ADI: attrition due to illness; ADD: attrition due to death; AaR: attrition at random
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Patients who missed an assessment because of being in hospital are classified as attrition due to 
illness
MORECare summaries account for both expected and not expected data
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